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ABSTRACT 
     Gastric dilatation-volvulus (GDV) is a life-threatening condition occurring primarily 
in large-breed dogs.  Serious consequences of GDV include hypovolemic shock, sepsis, 
cardiac arrhythmias and death.  Many systemic and metabolic changes occur leading to 
these complications. This study was designed to characterize changes in the content of 
adenosine triphosphate (ATP) and cellular permeability of gastric and jejunal mucosa 
during gastric dilatation-volvulus (GDV).  Our hypothesis stated that experimental GDV 
would result in a decrease in ATP content and cellular integrity of the gastric and 
intestinal mucosa that may improve after decompression and derotation of the stomach.   
     Fifteen medium-to-large mixed-breed male dogs were randomly divided into three 
groups:  GDV dogs, Ischemia dogs and Control dogs.  All dogs were maintained on gas 
anesthesia for 210 minutes.  The GDV dogs had a GDV for 120 minutes with a 90-
minute period of decompression, gastric derotation and reperfusion equaling 210 minutes.  
The Ischemia dogs had a similar GDV created and maintained for 210 minutes.  The 
Control dogs were maintained on anesthesia for the entire 210 minutes without gastric 
manipulation. 
     Tissue samples were taken in all dogs from the fundus, pylorus and jejunum at 0 
(baseline), 120 and 210 minutes.  Quantification of mucosal ATP (µg/ml) was 
accomplished using high performance liquid chromatography (HPLC).  Mucosal cellular 
permeability was evaluated using Ussing chambers by measuring conductance over 180 
minutes (∆Gt). 
     A significant decrease in ATP below baseline occurred in the fundic mucosa in the 
Ischemia dogs.  A significant decrease in ATP was seen in the jejunual mucosa in GDV 
 ix 
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and Ischemia dogs between baseline and 120 minutes; however, a return to baseline 
levels was seen in GDV dogs from 120 to 210 minutes. 
       No significant change in Gt from baseline was seen in the fundic mucosa in any 
dogs.  A significant increase in Gt was seen in the jejunal mucosa in the GDV and 
Ischemia dogs between baseline and 120 minutes.  The increase in Gt continued from 120 
to 210 minutes and was most profound in the GDV dogs. 
     The decrease in fundic ATP did not coincide with permeability changes.  
Interestingly, the jejunum showed profound changes in both ATP concentration and 
permeability.  It is the authors’ opinion that with the decrease in ATP concentration and 
loss of cellular integrity in the jejunal mucosa, the jejunum could be implicated as a 

















1.1  INTRODUCTION 
     Gastric dilatation-volvulus (GDV) is a life-threatening disease characterized by an 
accumulation of air in the stomach, malpositioning of the stomach on its long axis and an 
increase in intraluminal gastric pressure.1-3 Gastric dilatation with and without volvulus 
has been reported in man, dogs, monkeys, horses, ruminants, pigs, cats, foxes, mink, 
rabbits, nutria, guinea pigs, rats and mice.4  In dogs, GDV appears to be a polygenic 
disease occurring most frequently in older, large, deep-chested purebred canines.5-8 The 
incidence of this disease in dogs is estimated to be between 0.8% and 2.8% of emergency 
cases.9  Profound mechanical and physiologic effects of GDV include splanchnic 
vascular compromise, hypovolemia, cardiac arrhythmias, local and vascular systemic 
collapse, shock, disseminated intravascular coagulation and death.9-11  These changes 
require prompt medical and surgical therapy.  Despite appropriate therapy, mortality 
remains as high as 15-25% and may be greater for dogs with gastric necrosis.6,9,12-14 
     Gastric dilatation-volvulus is characterized by ischemia and inadequate tissue 
perfusion primarily due to the mechanical occlusion of the caudal vena cava and portal 
vein during dilatation and volvulus.15    Microscopic pathology includes both gastric and 
intestinal mucosal edema, hemorrhage and necrosis.16  The damage to the mucosa may 
allow transmural translocation of bacteria and subsequent bacteremia, and may contribute 
to viscus perforation.11,16-18 
     With prolonged and sustained reduction in tissue perfusion, a decrease in cellular 
membrane function due to decreased blood flow during ischemia with increased 
consumption and decreased production of adenosine triphosphate (ATP) is expected.19  
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Since ATP is responsible for maintenance of cellular membrane function and structure, 
tissue respiration, carbohydrate metabolism and intracellular energy-requiring functions, 
the depletion of gastric and intestinal mucosal ATP during GDV may be in part 
responsible for loss of mucosal integrity.11,20 
     This study was designed to characterize the changes in the ATP content and the 
cellular integrity of the mucosa of the stomach and jejunum from dogs during 
experimentally-induced GDV. 
1.2  ANATOMY AND PHYSIOLOGY 
1.2.1 STOMACH – The canine stomach is a saclike enlargement of the alimentary 
canal between the esophagus and the duodenum.21  The basic form of the stomach 
is that of a J-shaped, curved structure and ranges in capacity from 0.5 to 6.0 
liters.22 
     The esophagus enters the stomach at the cardia, which lies to the left of 
midline and is in direct contact with the liver.22  The stomach continues with a 
blind sac, the fundus, which lies to the left and dorsal to the cardia.  The stomach 
body lies to the right of midline and connects the cardia and the fundus to the 
pylorus, which forms the outlet to the duodenum.  The greater curvature of the 
stomach is convex in shape and connects the cardia to the pylorus.23  The greater 
curvature is located to the left and ventrally while the lesser curvature is concave 
in shape and lies opposite to the greater curvature and is located to the right and 
dorsally.  The greater and lesser curvatures give the stomach its sharp bend from 
left to right (Figure 1.1). 
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Figure 1.1 – The regions of the stomach of the dog (Evans HE. Miller's Anatomy 
of the Dog23; copyright permission pending.) 
     The wall of the stomach is comprised of four distinct layers.  The serosa covers 
almost the entire organ and adheres to the underlying muscle, except along the 
greater and lesser curvatures where it is continuous with the omenta.22  The next 
layer is the muscular layer, which consists of three layers of smooth muscle.  The 
layers are described as the outer longitudinal layer, the middle circular layer and 
an incomplete, internal oblique layer.21,22,24  The submucosa layer forms a strong 
elastic layer of tissue that more firmly attaches to the mucosa than to the 
muscularis.23  This layer contains vascular and nerve bundles.  The mucosa is 
divided into three distinct layers:  a columnar surface epithelium, a glandular 
lamina propria and a lamina muscularis mucosae.23  (Figure 1.2)  The surface 
epithelium is covered with mucus and varies in color depending on the content of 
gastric glands. 
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     The mucosa is the most metabolically active portion of the stomach demanding 
80% of the total gastric blood flow.11,25,26 
     The stomach is considered a dilated portion of the digestive tract where food is 
stored and digestion begins.27  The stomach is divided into regions that are 
separated according to specific cell types within the mucosal layer.  The cardiac 
and pyloric regions possess glands that primarily secrete mucus and the gastric 
glands of the fundus and body primarily secrete hydrochloric acid and pepsinogen 
by parietal and neck chief glands.21,22,24,27,28 
 
Figure 1.2 – The layers of the stomach wall of the dog (Evans HE. Miller's 
Anatomy of the Dog23; copyright permission pending.)  
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     The stomach is considered a dilated portion of the digestive tract where food is 
stored and digestion begins.27  As mentioned previously, the stomach is divided 
into regions that are separated according to specific cell types within the mucosal 
layer.  The cardiac and pyloric regions possess glands that primarily secrete 
mucus and the gastric glands of the fundus and body primarily secrete 
hydrochloric acid and pepsinogen by parietal and neck chief  glands.21,22,24,27,28 
     The stomach is innervated by sympathetic fibers from the celiac plexus and by 
parasympathetic fibers from two vagal trunks.21-23,28  Nervous activity of the 
stomach is reciprocal.  The parasympathetic action increases gastric stimulation 
whereas the sympathetic fibers augment the strength of peristalsis.28 
     The primary blood supply of the stomach is the left and right gastric arteries, 
which course along the lesser curvature and the left and right gastroepiploic 
arteries, which run along the greater curvature of the stomach.23  Also, a portion 
of the terminal branches of the splenic artery supplies the fundic portion of the 
stomach.(Figure 1.3) 
     Venous drainage is accomplished by the left gastric and left gastroepiploic 
veins which empty into the gastrosplenic vein and the right gastric and right 




Figure 1.3 – The blood supply of the stomach of the dog. (Evans HE. Miller's Anatomy 
of the Dog23; copyright permission pending.) 
1.2.2 JEJUNUM – The jejunum comprises approximately 85-90% of the total length 
of the small intestine and connects the duodenum to the ileum.24,27  The jejunum 
begins caudal to the root of the mesentery at the duodenojejunal flexure and is 
located ventrocaudal to the empty stomach.23  The jejunum is composed of four 
layers.  The outermost serosa is composed of peritoneum, except along the lines 
of mesenteric attachments.23  The muscular layer is composed of a thin outer 
longitudinal layer and a thick, inner circular layer.23  Similar to the stomach, the 
mucosa contains vascular, lymphatic and nerve bundles and serves to loosely bind 
the muscular and mucosal layers.24  The mucosa of the jejunum contains rugae 
that are covered by both 0.5-1 mm long intestinal villi and intestinal glands 
(crypts) that open between the villi.21-24,28  Both of these structures increase the 
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surface area of the mucosa in the jejunum.27  The surface of the villi is columnar 
epithelial cells interspersed with mucus-containing goblet cells.28  The intestinal 
crypts are also lined by columnar epithelial cells.28 
     The epithelium of the jejunum functions in the active and passive transport 
during digestion.29  Digestion is continued with secretion of an alkaline fluid 
containing mucus and enterocrinin, which stimulates secretion of other digestive 
enzymes and mucus.28-30 
     The blood supply of the jejunum is derived primarily from the cranial 
mesenteric artery via 12 to 15 direct branches. 21,23  (Figure 1.4)  The jejunum is 
drained by veins emptying into the portal vein.23  Over 75% of the blood entering 
the bowel wall is directed to the mucosal tissues, whereas 20% of the blood is 
distributed to the muscularis and serosal layers.31 
1.3 – ETIOLOGY AND PATHOLOGY OF GASTRIC DILATATION-VOLVULUS 
1.3.1 ETIOLOGY – An etiology for GDV has not been proven; however, multiple  
theories and predisposing factors have been proposed.  Rather than one etiologic 
factor of GDV, several factors are potentially responsible for initiation and 
progression of the disease.   
     Because GDV is primarily a disease of large-breed dogs, body conformation as 
a risk factor for GDV has been examined.  Gastric dilatation-volvulus is reported 
more often in large-breed dogs and there appears to be over-representation of 
Great Danes, akitas, bloodhounds, collies, Irish setters, Saint Bernards, 
weimaraners, rottweilers and Gordon setters.1,3,6,7  Most recently, the relationship 
between breed size and thoracic conformation have been closely examined.  Dogs 
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with the deepest thorax relative to width ratio had a significantly greater risk of 
GDV than those with a shallow thorax, but an exact explanation on why this risk 
factor contributes to this disease process is vague.7,32-34  It has been suggested that 
increases in thoracoabdominal dimensions may influence the resting position of 
the cardia and abdominal esophagus thereby impairing the ability of the dog to 
eructate and, hence gastric distention may initiate the disease process.11   
 
Figure 1.4 – The blood supply of the jejunum of the dog.  (Evans HE. Miller's Anatomy 
of the Dog23; copyright permission pending.) 
 9 
     Laxity of the gastric ligaments (hepatoduodenal and hepatogastric) has also 
been examined as a potential risk factor for GDV.  Though the stomach is loosely 
held in position by a series of ligamentous attachments, these attachments do not 
prevent clockwise rotation.32  No histologic difference was observed in the 
ligamentous attachments from dogs with GDV and from normal controls.  
Although it was concluded that though no cause can be inferred from gastric 
ligamentous composition, an elongated gastric ligament may permit gastric 
volvulus and predispose dogs to GDV.35  A causal relationship between the actual 
length of the ligaments and development of GDV has not been evaluated. 
     Dietary habits including frequency of feedings, volume of feeding and 
composition of diet have been implicated as risk factors for GDV.  Dogs fed one 
large meal a day appear at increased risk for GDV when compared with dogs fed 
multiple small meals.1,2,11  No theory for why once daily feeding is a risk factor 
has been accepted, but proposals such as an increase in intragastric volume 
distorting gastric anatomy and increasing the propensity of the stomach to twist 
on its long axis, and changes in the rate of gastric emptying or myoelectrical 
damage due to gastric distention have been suggested.1,2,11,32  Particle size of food 
has also been implicated as a risk factor.  In a case-control study, Theyse, et al 36, 
showed that food particles >30 mm in size decreased the risk of GDV in dogs. 
     Vigorous postprandial exercise with a distended stomach is also proposed to be 
a risk factor for GDV.10,11  The potential for GDV exists due to the gastric 
dilatation caused by consumption of food and water followed by accumulation of 
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air due to exercise; however, a pattern linking feeding and postprandial exercise 
habits to GDV has not been established. 
     An acute dysfunction of pyloric outflow due to gastric malposition or 
myoelectrical dysfunction causing a delay in gastric empyting has been suggested 
as a potential risk factor of GDV.11,32  Pyloric dysfunction can be a manifestation 
of stress, and can be altered by anesthetic agents and other biochemical 
disturbances.1  A more recent study examined dogs recovering from GDV and 
found that no consistent pattern of gastric emptying was observed.37  Thus, it is 
difficult to determine any role mechanical or functional pyloric outflow 
obstruction may have in the pathogenesis of GDV.  
     An inability to relieve gastric pressure by effective eructation or vomiting is 
another risk factor that could contribute to the development of GDV.11  It is 
proposed that either gastric volvulus physically, an abnormality with the 
gastroesphageal junction or a defect in vagal reflexes prevents eructation and 
allows dilatation to occur.11,32 
     In a study by Leib, et al,38 increases in serum gastrin concentrations were 
proposed as a potential risk factor for GDV.  Gastrin may initiate GDV by its 
trophic actions on gastric mucosa.  This proliferation of gastric mucosa may 
increase the caudal esophageal sphincter pressure, delay gastric emptying, 
promote gastric mucosal hypertrophy and promote pyloric muscular 
hypertrophy.38,39  However, endogenous administration of gastrin did not induce 
these proposed changes.40 
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     Other risk factors that have been explored include temperament and age.  It has 
been reported that personality is a possible risk factor for GDV.  In a study of 
1,934 dogs who were described as “happy” or “easy-going” were at a decreased 
risk for the development of GDV and those dogs that were characterized as 
“fearful” had an increased risk of developing the disease.  The same study showed 
a relationship between increased risk and increasing age. It was suggested in this 
study that the pathogenesis of GDV is linked to an underlying disease process that 
increased with age.6  The risk, however, is not associated with an increase in 
mortality.9 
1.3.2 PATHOPHYSIOLOGY OF GDV  
• Gastric 
     Though the precise initiating factors of GDV are not clearly understood, the 
general disease process begins with an accumulation of gas, food or fluid 
combined with a functional or mechanical obstruction of the pylorus or 
gastroesophageal junction.10,11,17,32  The source of the gas is possibly from 
aerophagia or bacterial fermentation, or reaction of gastric acid with bicarbonate. 
Evaluation of the composition of the gastric gas has been more consistent with 
aerophagia.41 
     Though controversial, it is believed that dilatation occurs prior to volvulus; 
however, volvulus can occur without dilatation and dilatation can occur without 
volvulus.10,11  The anatomic malpositioning of the stomach begins with the 
displacement of the pylorus from its normal position along the right abdominal 
wall towards the ventral midline.  The pylorus then moves cranially and toward 
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the cardia adjacent to the esophagus and the left abdominal wall.  The fundus and 
body are displaced dorsally toward the right abdominal wall.  This progression of 
malpositioning is the most characteristic of GDV.17  The degree of gastric 
volvulus generally ranges from 90 to 360 degrees. 
     When viewing the abdomen at surgery, the ventral leaf of the omentum covers 
the displaced stomach and is an indication that gastric volvulus is present.  
Following decompression, the pylorus is grasped while the body and fundus of 
the stomach are pushed dorsally.  The pylorus is then carefully manipulated 
ventrally resulting in a repositioning of the stomach.  A thorough examination of 
the stomach, intestines and other abdominal organs should be performed.  Since 
the spleen is attached to the greater curvature of the stomach, it is often displaced 
and should be carefully inspected for hemorrhage or damage. 
     The accumulation of gas with spontaneous GDV results in a dramatic increase 
in intragastric pressures.42  A mean gastric pressure of 23 mm of Hg was reported 
in 20 naturally occurring cases of GDV; however, higher gastric pressures are 
believed to occur.43  An intraluminal gastric pressure of 30 mm Hg has been 
shown experimentally to be sufficient to create cardiovascular obstruction and 
hemodynamic derangements similar to spontaneous GDV.26,42 
     Gastric pathology in GDV is varied depending upon the degree of vascular 
compromise.  A 92%  decrease in gastric surface tension is seen with GDV 
resulting in a decrease in gastric blood flow and subsequent ischemia.11,44  
Pathologic changes range from mild edema and hemorrhage of the layers of the 
stomach to full-thickness necrosis and perforation.10  However, the most profound 
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changes are usually seen in the gastric mucosa.25,26  Necrosis and infarction 
typically occur along the greater curvature of the stomach in the area of the short 
gastric vessels.17 
• Cardiovascular 
Blood flow – Gastric dilatation causes direct compression of the major vessels of 
the abdomen resulting in an increase in caudal vena cava and portal vein 
pressures.45,46  Gastric volvulus further contributes to hemodynamic abnormalities 
by interfering with gastric venous drainage.15  With caudal vena cava 
compression, there is sequestration of blood in the splanchnic circulation and 
reduced cardiac venous return.25    With decreased splanchnic circulation, 
decrease in cardiac output and increases in vascular pressures, a severe reduction 
of blood flow to the abdominal viscera is observed.44,47 
Shock – Shock occurs as a result of many pathophysiologic events of GDV.  
Venous congestion and decreased venous return initiate hypovolemic shock.11,25  
Decreased venous return is believed to be the primary cause of reduced cardiac 
output and reduced mean arterial blood pressure during GDV.  In approximately 
50% of dogs with experimentally-induced GDV, the liver becomes congested due 
to direct compression on the hepatic vasculature.11  Hepatic congestion and portal 
hypertension leads to an inability of the hepatic reticuloendothelial system to 
eliminate bacteria and toxins.10,17,48  Endotoxic and septic shock occur because of 
portal venous occlusion, impairment of reticuloendothelial system and the loss of  
the gastrointestinal mucosal barrier that leads to translocation of bacteria and 
endotoxins into the systemic circulation can then occur.18,25 
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• Clinical pathology 
Packed cell volume –  During GDV, hemorrhage occurs from avulsion of 
vessels as the stomach rotates.  Administration of shock volumes of 
intravenous crystalloid fluids (90ml/kg/hr) can result in a sharp decrease in 
hematocrit, as low as 20%.11  Experimentally, transient increases in PCV 
are observed during gastric dilatation.  Packed cell volume peaks after 
decompression and then returns to baseline.46  The reason for this increase 
is unclear, but the transient rise can be attributed to a release of 
sequestered red blood cells.11  Post-surgically, hemorrhagic gastritis and 
mucosal ulceration may contribute to a decline in red blood cell volume.10   
Total protein – Serum total protein concentrations tend to mimic changes 
in PCV, increasing during dilatation and returning to baseline after 
decompression of dogs with experimentally-induced GDV.46  Gastric 
mucosal ulceration and gastritis cause sequestration of protein into the 
gastric lumen resulting in hypoproteinemia.10 
Blood gas (acid/base) – Concentrations of lactic acid are increased in 
GDV during gastric dilatation as a result of anaerobic tissue metabolism 
and is reflected as a metabolic acidosis.11,46  However, this is an 
inconsistent change.  
     A later study of 20 dogs with acute, naturally-occuring GDV showed 
no significant changes in anion gap or arterial bicarbonate concentration 
with normal blood pH, blood gas concentrations and anion gap.49 
 15 
• Respiratory 
     Dilatation of the stomach directly impinges upon the depth of thoracic 
excursion, thereby decreasing ventilatory capacity.25  An increase in inspiratory 
and expiratory resistance leads to a marked decrease in lung compliance.11  Also, 
with the mechanical obstruction of gastric dilatation, venous return via the caudal 
vena cava is decreased leading to a reduced volume of blood available for 
oxygenation.10,25  These changes ultimately lead to inadequate alveolar 
ventilation, ventilation-perfusion mismatch and hypoxemia.25 
1.4  ISCHEMIA AND REPERFUSION 
     In GDV, an increase in intraluminal gastric pressures, gastric edema, venous outflow 
obstruction, infarction of the microvasulature, reduction in cardiac output and 
compromise of the gastric arteries leads to a decrease in gastric surface oxygen tension.44  
This decrease in surface oxygen tension is a reflection of profound gastric ischemia.10  
Ischemia, defined as a reduction in oxygenated blood flow, will cause cell death due to 
low or no blood flow periods, injury because of inadequate metabolism substrate 
availability and disturbed gastric and intestinal mechanisms such as active oxidant 
formation and inhibition of intrinsic protective systems.31  The mucosa of both the 
stomach and intestine have high metabolic demands and require 75-80% of the blood 
supply to these organs.  This results in greater vulnerability to decreased blood flow and 
an increased risk of mucosal injury.11,31 
     Cellular hypoxia subsequent to ischemia, increases the utilization and demand for 
adenosine triphosphate (ATP).  Increased utilization leads to an increase in the rapid 
degradation of ATP to adenosine diphosphate (ADP), then adenosine monophosphate 
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(AMP), adenosine, inosine and finally hypoxanthine.50  Also, synthesis of ATP from 
adenosine monophosphate (AMP) is decreased leading to inadequate energy production 
required for cell metaoblism.  The decrease in available energy occurs because during 
periods of ischemia, there is an increase in catabolism of AMP to hypoxanthine.31  
Alternate pathways, such as anaerobic glycolysis, are used to meet the metabolic 
demands of the cells.10 
     The loss of ATP as an energy source causes a loss of cellular ion gradients by 
depressing ATP-dependent membrane pumps.10  Therefore, the sodium-potassium pump 
is rendered incapable of exchanging intracellular sodium leading to hypersomolarity, 
water influx and cellular edema.10  An increase in cytosolic calcium also occurs and 
results in activation of cellular kinases and proteases.20 
     Since synthesis of ATP is decreased during ischemia, there is a greater conversion of 
AMP to hypoxanthine.51  (Figure 1.5)  With an increase in hypoxanthine production, a 
concurrent increase in conversion of xanthine dehydrogenase into xanthine oxidase also 
occurs.31  Xanthine oxidase generates free radicals that damage mucosal cells by causing 
disulfide formation in membrane proteins and by lipid peroxidation of cell 
membranes.31,52  Though many theories have been studied, ischemia and subsequent 
cellular hypoxia appears to trigger this conversion of xanthine dehydrogenase to xanthine 
oxidase.53 
     Paradoxically, it is the reoxygenation or reperfusion of tissue that results in molecular 
oxygen reaction with hypoxanthine and xanthine oxidase to produce oxygen free radical 
metabolites in the form of superoxide, hydrogen peroxide and hydroxyl radicals. 53-56  
(Figure 1.6, equations 1 and 2)  The further reduction of hydrogen peroxide to a hydroxyl 
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radical occurs in the presence of iron via the Haber-Weiss reaction. 57,58  (Figure 1.6, 
equation 3)  
 
 
Figure 1.5 – Ischemia/reperfusion cascade 
  
hypoxanthine + 2O2 + H2O → xanthine + 2O2
- + 2H+       (1) 
2O2
- + 2H+ → H2O2 + O2            (2) 
O2- + H2O2 + Fe
3+ →  O2 +  OH.  +  OH- + Fe2+               (3) 
Figure 1.6 – Reactions for formation of superoxide radicals (equation 1), hydrogen 
peroxide (equation 2) and hydroxyl radicals (Haber-Weiss reaction, equation 3) 
     Superoxide radicals and hydroxyl radicals cause lipid peroxidation, enhanced 
prostaglandin production, increases in membrane permeability and damage to nucleic 
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acids leading to further mucosal damage and cell death.57,59,60  Concurrently, the oxygen 
radicals also trigger the accumulation of neutrophils initiating inflammatory processes 
that lead to severe mucosal damage, whereas phospholipase A2 also initiates reperfusion 
mucosal damage.61 
     Cellular damage due to ischemia, hypoxia and reperfusion has been extensively 
evaluated.  In a study by Perry, et al 62, reintroduction of oxygen to ischemic gastric 
tissue was controlled in order to evaluate the rate at which oxygen radicals were 
produced.  The investigation indicated that if the stomach was vascularly perfused with 
low PO2 blood before return to normal arterial perfusion, cellular damage was reduced.  
Consequently, it could be implied that the initial hypoxia is responsible for only part of 
the injury seen with ischemia and reperfusion.62 
     Treatment modalities have been directed at attenuating the cellular damage of 
ischemia and reperfusion.  In experimentally-induced GDV, allopurinol (a xanthine 
oxidase inhibitor), U74006F (a lipid peroxidation inhibitor), deferoxamine (an iron 
chelator) and dimethylsulfoxide (free radical scavenger) were used to examine damage 
caused by reperfusion injury and as a potential treatment for damage associated with 
reperfusion injury.52,63  All of these drugs were administered at various times prior to 
gastric decompression, gastric repositioning and tissue reperfusion.  The conclusions 
were that the lipid peroxidation inhibitor and the deferoxamine may be useful additions to 





1.5  BIOCHEMISTRY OF ATP 
     Free energy is required for three major purposes in mammalian cells:  synthesis of 
molecules from simple precursors, mechanical work in muscle contraction, and active 
transport across cell membranes.  The free-energy donor most frequently utilized for 
these purposes is adenosine triphosphate (ATP).64   
     Adenosine triphosphate is a combination of adenine, ribose, and three phosphate 
radicals.65  High-energy bonds connect the phosphate radicals and energy is released as 
each of these phosphoanhydride bonds is broken.  After one of the phosphate bonds is 
broken, ATP becomes adenosine diphosphate (ADP) and with the loss of the next 
phosphate bond becomes adenosine monophosphate (AMP).  (Figure 1.7) 
     Adenosine triphosphate is an immediate donor of free energy and has the ability to 
enter many coupled reactions to extract energy from food sources and other physiological 
mechanisms.  Because ATP is an immediate source of energy, the turnover of ATP is 
very high.64,65  A continuous regeneration of ATP is necessary to meet the basic energy 
needs of mammalian cells.  Therefore, ATP must be continuously replenished by 
synthesis from ADP.  As protons are pumped across cell membranes, a proton-motive 
force provides the power needed to synthesize large quantities of ATP from ADP.64 
     The degradation of carbohydrates, fats and proteins results in cellular respiration that 
provides energy to drive the synthesis of ATP.66  The degradation of glucose to carbon 
dioxide and water is the primary source of ATP.  In glycolysis, a molecule of glucose is 
degraded in a series of enzyme-catalyzed reactions to produce two molecules of pyruvate.  
For each glucose molecule, two ATP are consumed and four ATP are produced resulting 
in a net yield of two ATP per molecule of glucose coverted to pyruvate. 66  (Figure 1.8)  
 20 
 
Figure 1.7 – Chemical structure of ATP, ADP and AMP 
     The fate of pyruvate is variable, but in aerobic conditions, the pyruvate is oxidized, 
with loss of its carboxyl group as CO2, to yield the acetyl group of acetyl-coenzyme A.  
The acetyl group is then oxidized to CO2 by the citric acid cycle.  A total of two ATP 
molecules are formed for each molecule of glucose metabolized. 65  (Figure 1.9) 
Hydrogen atoms are released at different points in the citric acid cycle.  A total of 24 
hydrogen atoms are produced for each molecule of glucose.  Twenty of these 24 
 21 
 
Figure 1.8 – Glycolysis 
hydrogen atoms are released and catalyzed by dehydrogenase.  The hydrogen ions (bound 
with NAD+ and unbound) enter into the electron transport chain for ATP production.  The 






Figure 1.9 – Citric acid cycle 
 
     It is believed that 90% of the total ATP formed by glucose degradation is formed 
during oxidation of hydrogen atoms.  This oxidative reaction splits each hydrogen atom 
into a hydrogen ion and an electron that are passed to oxygen in the mitochondrial matrix 
into the electron transport chain.  The electrons combine oxygen with water to form 
hydroxyl ions and the hydrogen and hydroxyl ions combine with each other to form 
water.  The electron transport reactions provide large amounts of energy for the synthesis 
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of ATP in the mitochondria.  The formation of ATP in this manner is called oxidative 
phosphorylation.65,66 
     The electron that is produced enters the electron transport chain, where large amounts 
of energy are released to drive the synthesis of ATP.  The energy is used to transport 
hydrogen ions from the inner matrix of the mitochondrion into the outer chamber of the 
mitochondrial membrane.  This results in a higher concentration of positive charges in the 
outer membrane, while a strongly negative charge exists in the inner matrix of the 
mitochondrion.65 
     The next step in oxidative phosphorylation is to convert ADP to ATP.  Adenosine 
triphosphate synthetase is a large protein molecule that traverses the mitochondrial 
membrane and acts as a conduit for hydrogen ions.  The energy derived from the 
hydrogen ion flow is used to convert ADP into ATP by adding an additional high-energy 
bond.65  A total of 38 ATP molecules are formed from each glucose molecule degraded to 
carbon dioxide and water.65 
     A fate of pyruvate that is relevant to the hypoxic cellular environment associated with 
GDV, is the reduction of pyruvate to lactate via lactic acid fermentation.  Lactate is a 
product of glycolysis.66  A small amount of energy can still be delivered to the tissues 
because the breakdown of glucose to pyruvic acid does not require oxygen.  However, 
because this reaction cannot take advantage of oxidative phosphorylation, this process is 
wasteful of the glucose molecule that is broken down during glycolysis.  Thus, the release 
of glycolytic energy to cells can meet metabolic needs for a  short period of time.65 
     It is plausible that during cellular hypoxia associated with GDV, a decrease in oxygen 
availability will result in a reduction in cellular ATP.67  As gastric mucosa oxygen 
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tension decreases and aerobic production of ATP decreases, anaerobic metabolism to 
produce ATP is likely to occur.10  It is hypothesized that anaerobic metabolism is unable 
to sustain the metabolic needs of the tissue leading to an overall decrease in cellular ATP.  
Ultimately, this may contribute to cell death.31 
1.6  HIGH PERFORMANCE LIQUID CHROMATOGRAPHY 
     High performance liquid chromatography (HPLC) is a process in which mixtures are 
separated and analyzed for particular substances.  Chromatographic separation of 
substances is the result of interactions between sample molecules and the stationary and 
moving phases during the chromatographic process.  Modern HPLC offers a convenient, 
accurate, expedient method to derive difficult separation of specific substances. 
As opposed to other methods of chromatographic substance separation, HPLC is not 
limited by sample volatility or thermal instability.  It is best suited for the separation of 
specific macromolecules and ionic species.  With HPLC, high-pressure pump solvent 
delivery is used to better separate, detect and quantify various substances. 
     In modern HPLC, a closed, reusable column is used as a conduit and a platform for 
separation for a precise sample injection.  The solvent is introduced into the column and 
to the sample by high-pressure pumps.  These pumps allow for a controlled, rapid flow of 
solvent through the columns.  This method of separation using the high-pressure pumps 
also leads to greater reproducibility with high accuracy.68 
     Theoretically, the process of HPLC occurs in a step-wise manner.  A precise sample is 
applied to the column.  Next, the solvent (mobile phase) begins to flow through the 
column, the solvent is delivered by a high-pressure pump that moves the sample 
molecules along the column and results in sample separation.  The detection and 
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quantitation of the sample molecules is achieved with various detectors.  Differential 
migration allows separation of the different compounds moving through the column.  For 
example, the most soluable compounds become separated and leave the column first.68,69 
     The success of separation depends on the type of column packing and mobile phase, 
the length and diameter of the column, the mobile-phase flow rate, separation 
temperature and sample size.68 
     High performance liquid chromatography has been used for the separation and 
determination of extracellular purines.  The quantitation of ATP, ADP and AMP has been 
separated by HPLC from biopsies of heart tissue, skeletal muscle, brain, liver and 
intestinal mucosa of various species.69,70 
1.7  USSING CHAMBERS 
     The use of the voltage clamp and Ussing chamber are used to define the ability of 
tissue to detect the presence of active and passive transport.  Active transport is evaluated 
by eliminating the electrical gradient and measuring the sodium secretory response which 
generates the gradient.71 
     The tissue or cell culture monolayer is positioned between two compartments and 
mounted in the chamber.  The transport of ions between serosal and luminal surfaces of 
tissue is measured.  Active transport is measured in the Ussing chamber by using a 
voltage clamp.  The use of the voltage, short-circuit current (Isc) and specific current 
settings is designed to eliminate the driving force for ion movement and, since the current 
is balanced across the membrane (via agar bridges), the potential for active transport is 
isolated and defined in the mounted tissue. 
 26 
In the case of passive transport, the short circuit is closed and electrolyte transport in the 
tissue occurs by passive ion transport conducted down an electrochemical gradient.  This 
passive diffusion is measured as transmural potential difference (PD). 
     Total tissue conductance (Gt) reflects the contribution of both active and passive ion 
movements across the tissue and is calculated using Ohm’s law.72  Total tissue 
conductance is directly related to the permeability of tissue and can be indicative of 
function and viability.73  Gastrointestinal permeability is characterized as that property of 
the tissue that modifies the permeation of solutes across or into the gastrointestinal tract.74  
Total tissue resistance is related to conductance by permeability in inverse proportion. 
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CHAPTER 2.  ADENOSINE TRIPHOSPHATE VALIDATION IN CANINE 





     Adenosine triphosphate (ATP) is essential to cellular metabolism.1  In order to explore 
the effects of varying conditions that alter cellular function, a method to quantify the 
cellular ATP content is required.  High performance liquid chromatography has been 
successfully used to quantify tissue concentrations of ATP, adenosine diphosphate (ADP) 
and adenosine monophosphate (AMP) from multiple species.2 
     Chromagraphic separation of substances is the result of interactions between sample 
molecules and the stationary and moving phases of sample and solvents during the 
chromatographic process.  High performance liquid chromatography is not limited by 
sample volatility or thermal stability; therefore, it is ideal for separation of 
macromolecules, ionic species and a wide variety of other high-molecular weight 
compounds.3 
     In HPLC, a column is used as a conduit and platform for separation of a precise 
sample injection.  Concurrently, the solvent is introduced into the column with the 
sample by high-pressure pumps.  This method of separation leads to a greater 
reproducibility with high accuracy.  Differential migration results in the varying rates of 
movement of the different compounds moving through the column.  Therefore, the most 
soluble compounds become separated and leave the column first.3 
     Depletion of cellular ATP may be a critical reflection of the damage to the gastric and 
intestinal mucosa that is seen subsequent to an ischemic insult.  The ability to separate 
and measure cellular ATP concentration and its metabolites could be useful in exploring 
the relationship between fluctuations in cellular ATP, ADP and AMP and its role in 
ischemic tissue injury. 
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     The following is a description of a validation (separation and extraction) method for 
ATP, ADP and AMP using HPLC on the canine gastric and jejunal mucosa. 
2.2  MATERIALS AND METHODS 
2.2.1 Animals – This study was approved by the Institutional Animal Care and Use  
Committee of Louisiana State University.  Gastric and jejunal mucosal tissue was 
obtained from dogs prior to euthanasia for reasons unrelated to gastrointestinal 
disease.  Full-thickness tissue samples were harvested from the fundus region of 
the stomach and the proximal jejunum.  The tissue was then prepared by gently 
teasing the mucosa from the muscularis layer.  The mucosal tissue was partitioned 
into 5 mm x 5 mm portions, placed into cryotubes and immediately submersed in 
liquid nitrogen until frozen and stored at –70° C. 
2.2.2 Preparation of standards – Known standards of ATP, ADP and AMP were 
prepared for comparison against a tissue-spiked standards. 
     Standard compound amounts weighed were 0.0100 gm of ATP, 0.0104 gm of 
ADP and 0.0100 gm of AMP.  The amount of each compound that is weighed is 
dependent upon percent purity of each.  All standard compounds were then mixed 
in a liquid scintillation vial.  Using a volumetric flask, 10 ml of HPLC water was 
added.  The sample was then sonicated for five minutes and stored in the 
refrigerator, if necessary.  Concentration of the stock sample standard was 1 
mg/ml.  The concentrations chosen for extraction were 0.0 µg/ml, 0.05 µg/ml, 0.1 
µg/ml, 0.2 µg/ml, 0.5 µg/ml, 1.0 µg/ml, 2.5 µg/ml and 5.0 µg/ml. 
     Two thousand µL of HPLC water was added to six 5 ml test tubes.  These test 
tubes were labeled for concentrations:  0.0 µg/ml, 0.5 µg/ml, 1.0 µg/ml (2), 2.5 
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µg/ml and 5.0 µg/ml.  Using a 10µL Hamilton syringe, 1.0 µL was pipetted and 
discarded from the 0.5 µg/ml test tube, 2.0 µL was pipetted and discarded from 
the 1.0 µg/ml test tubes, 5.0 µL was pipetted and discarded from the 2.5 µg/ml test 
tube and 10.0 µL was pipetted and discarded from the 5.0 µg/ml test tube.  Equal 
amounts of stock standard solution were added to the test tubes to equal 2000 µL 
per test tube.  Each tube was vortexed until mixed.  In order to make standard 
concentrations, 0.05 µg/ml, 0.1 µg/ml and 0.2 µg/ml dilutions of the 0.5 µg/ml and 
1.0 µg/ml standards are necessary.  For the 0.05 standard, using a 10 ml 
volumetric flask, 1 ml of the 0.5 µg/ml standard solution and HPLC water was 
pipetted into the flask to equal 10 ml.  For the 0.1 µg/ml standard, using a 10 ml 
volumetric flask, 1.0 ml of the 1.0 µg/ml standard solution and HPLC water was 
pipetted into the flask to equal 10 ml.  For the 0.2 µg/ml, using a 5 ml volumetric 
flask, 1.0 ml of the 1.0 µg/ml standard solution and HPLC water was pipetteted 
into the flask to equal 5 ml. 
     High performance liquid chromatography tubes were placed in a vial rack and 
labeled with number corresponding to test tubes.  A 4 mm syringe filter (Nalgene 
0.45 µm nylon membrane) was placed on a Leur-lock tip of a 1 mm tuberculin 
syringe.  The plunger was removed and the filter tip of the syringe unit was placed 
on the HPLC vial.  Using a glass Pasteur pipette, the contents of each test tube 
was placed into the syringe.  The syringe plungers were replaced and gentle 
pressure was supplied to inject the filtered stock sample into the HPLC vials. 
After filtration, HPLC injection caps were placed into racks in ascending order 
onto the HPLC auto-sampler carriage for analysis. 
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2.2.3 Tissue preparation – Within 24 hours after collection, the frozen samples were 
lyophilizeda and stored in a desiccator at –70° C until HPLC analysis. 
2.2.4 Adenine nucleotide validation – The method of separation and extraction was 
adapted from a method described by Tetens and Wynants.2,4 
     On the day of analysis, frozen samples were transported on ice to the 
laboratory.  Eight to 10 frozen tissue samples were cut into pieces from a parent 
segment of tissue and weighed (7-13 mg dry weight).  Each piece of tissue was 
then placed in an individual 10-ml conical tube on ice.  An individually calculated 
amount of iced cold perchloric acid (1 ml of 0.6 N HClO4/1.5 mg of dry weight 
tissue) was added to each sample. 
     Each sample was homogenized using a tissuemizerb.  The samples were 
centrifuged at 2,500 RPM at –5˚ C for 12 minutes.  One thousand two hundred to 
1,500 µL of tissue extract (supernatant) was removed from each conical tube and 
combined into a 15 ml conical tube. 
     Amounts of tissue extract and addition of 1 mg/ml stock standards and tissue 
















0.0  0.0 1200 
0.05 1.0 1199 
1.0 2.0 1198 
2.5 5.0 1195 
5.0 10.0 1190 
 
Two standard concentrations of the 1.0 µg/ml solution were made for dilutions.  
Dilutions were composed as listed in Table 2.2. 







0.05 200 µL of 0.05 µg/ml 1000 
0.1 200 µL of 1.0 µg/ml 1000 
0.2 400 µL of 1.0 µg/ml 800 
           
     With the 5 ml conical tubes on ice, 800 µL of ice-cold potassium bicarbonate 
was added dropwise to each tube.  The tubes were vortexed until thoroughly 
mixed, capped and centrifuged at -5˚ C at 2000 RPM for 15 minutes. 
     High performance liquid chromatography vials were labeled according to 
above concentrations.  Nalgene 0.45 µm nylon membrane filters were place on the 
 38 
Luer-lock tip of a 1 mm tuberculin syringe and placed over the top of each vial.  
The syringe plungers were removed and the samples were pipetted into the 
syringe for each corresponding vial.  The syringe plungers were then replaced and 
the contents were injected into the HPLC vials.   
     The HPLC vials were loaded into auto-sampler magazines and the ATP, ADP 
and AMP were separated by HPLC using an Alltech Adsorbosphere C 18 5 µm 
columnc.  The column was eluted by gradient, using 0.15M ammonium phosphate 
and methanol/acetonitril (50:50), at a gradient of 100% to 93% of ammonium 
phosphate over 10 minutes.  Detection of  the compound was performed by a 
diode-array detectord set at a peak of 260 nm.  The run time for each sample was 
10 minutes with a 5 minute post-run period.  The peaks were quantified by area 
under the curve and compared with peak area of known standards of ATP, ADP 
and AMP. 
2.3  RESULTS 
     Using the method described, the isolation and extraction of ATP, ADP and AMP were 
performed in a linear manner.  The extraction and isolation as a function of pre-
determined concentrations were confirmed with the linear representation with the 
resultant curves appearing parallel.  This linear relationship was appreciated in both the 
standard HPLC water standard and tissue-spiked standard curves.  (Figure 2.1)  This 
method is valid with a correlation coefficient of >0.995, which is within industry 
standards for acceptability. 
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     Figure 2.1 – Standard curve and tissue concentration of ATP (µg/ml) in 





The results for stomach and jejunum ATP, ADP and AMP concentrations are 













Table 2.3 – Tissue validation values for concentration of ATP, ADP and AMP (µg/ml) in  
  gastric and jejunal mucosa. 
 
ATP   
µg/ml Standard area Tissue standard area 
0 0.00 69.74. 
0.05 2.31 72.75 
0.1 5.13 68.76 
0.2 6.32 75.56 
0.5 20.73 87.6 
1.0 30.63 101.2 
2.5 94.17 141.05 
5.0 188.53 241.45 
ADP   
µg/ml   
0 0.00 34.98 
0.05 2.53 38.16 
0.1 5.47 38.45 
0.2 7.01 45.90 
0.5 24.02 56.69 
1.0 35.76 73.8 
2.5 111.15 127.65 
5.0 225.45 251.71 
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(Table 2.3 continued) 
AMP   
µg/ml   
0 0.00 18.69 
0.05 3.38 24.17 
0.1 6.84 27.63 
0.2 9.93 37.19 
0.5 31.99 52.18 
1.0 48.64 73.06 
2.5 145.12 144.22 




     The standard curve (calibration curve) generated in this study demonstrated that ATP, 
ADP and AMP could be isolated and extracted in a linear-dose response relationship.  
The calibration curve is a graphical reflection of the known amount analyzed and the 
concentration recovered and helps define the concentration limits of the extraction 
method.  The recovery of the standard samples should reflect a linear response as the 
amount of known sample should be equal to the amount recovered during the extraction.  
The correlation coefficient of the sample is critical in assessment of accuracy as it gives a 
measure of the fit of the calibration curve between data points.5  A correlation coefficient 
of >0.995 demonstrated that the method is capable of accurate extraction, isolation and 
quantification of ATP, ADP and AMP in a dose-response manner. 
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     Since the tissue-spiked standard curve was parallel to the standard curve, isolation and 
extraction of ATP, ADP and AMP from the gastric and jejunal mucosa was possible 
without any adverse effect on the evaluation by the presence of the tissue components, 
such as fats, proteins or other complex structures.  Visually, because the lines follow a 
parallel linear dose-response progression, the method of isolation, extraction and analysis 
is accurate and valid 
2.5  END NOTES 
a   FreeZone 4.5 liter freeze dry system, Model 77510, Labconco Corporation, Kansas 
City, MO 
 
b  Ultra-turrax T25, Tekmar Corporation, Cincinnati, OH 
 
c  Adsorbosphere C18 5U column, Direct-connect prefilter kit #28689, All-guard 
cartridge system #96041, Alltech Associates, Deerfield, IL 
 
d  HP 1090 liquid chromagraph, Agilent Technologies, Wilmington, DE 
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CHAPTER 3.  THE EFFECT OF EXPERIMENTAL GASTRIC DILATATION-
VOLVULUS ON ADENOSINE TRIPHOSPHATE CONTENT AND CELLULAR 
PERMEABILITY ON THE CANINE GASTRIC AND JEJUNAL MUCOSA 
 44  
3.1 INTRODUCTION 
     Gastric dilatation-volvulus (GDV) is a life-threatening condition characterized by an 
accumulation of air in the stomach, gastric malposition with an increase in intraluminal 
pressure and hemodynamic abnormalities that lead to shock.1,2  Appropriate therapy for 
GDV consists of gastric decompression, intravenous fluid support and surgical 
intervention to reposition the stomach.  Despite therapy, the proportion of affected dogs 
that die is at least 15 to 24% of cases, and is even greater if the dogs have concurrent 
gastric necrosis.2-5 
     Gastric dilatation- volvulus results in both gastric and intestinal mucosal edema, 
hemorrhage and necrosis.6  Mucosal damage may allow transmural translocation of 
bacteria and development of bacteremia.  Severe mucosal damage may be associated with 
full-thickness damage and later perforation.6-9 
     Gastric dilatation-volvulus is characterized by ischemia of gastric and intestinal tissue, 
as well as a generalized inadequate tissue perfusion primarily due to the mechanical 
occlusion of the caudal vena cava and portal vein during dilatation and volvulus.10  
Typically, ischemia will cause a decrease in cellular membrane function in the affected 
tissue with an increase in consumption and decrease in production of adenosine 
triphosphate (ATP).11 
     Since ATP is important for cellular functions that maintain membrane structure and 
function, tissue respiration, carbohydrate metabolism and other intracellular energy-
requiring functions, the depletion of gastric and intestinal mucosal adenosine triphosphate 
during GDV may reflect the loss of mucosal integrity.9,12 
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     This study evaluated the concentration of ATP, ADP and AMP in the gastric and 
jejunal mucosa, as well as changes in the mucosal integrity of dogs undergoing 
experimentally-induced GDV. 
3.2  MATERIALS AND METHODS 
     The study was approved by the Institutional Animal Care and Use Committee of 
Louisiana State University. 
3.2.1 Overview – Fifteen mixed breed male dogs weighing between 20 and 30 kg were 
randomly assigned to one of 3 groups (Control, GDV, Ischemia).  An anesthetic 
protocol of acepromazine (0.05 mg/kg) and butorphanol (0.2 mg/kg) as a 
premedication, thiopental sodium (15 mg/kg) as an induction agent and isoflurane 
and oxygen for gas anesthesia maintenance was used.  Initially, a balanced 
electrolyte solution (10 ml/kg/hr) was administered intravenously. 
3.2.2 Model – Dogs were placed on a heating pad in dorsal recumbancy and indwelling 
catheters were placed in the right femoral artery and left jugular vein for 
measurement of mean arterial pressure and central venous pressure, respectively, 
and for the purpose of blood sampling.  An indwelling urinary catheter was also 
placed and connected to a closed collection system for the purpose of quantitating 
urine output. 
     A ventral midline abdominal incision was made.  An indwelling catheter was 
placed in a jejunal vein for measurement of portal pressure.  In Control dogs no 
GDV was created; however, anesthesia was maintained for 210 minutes and 
samples were taken at designated times.  In GDV and Ischemia dogs, a 14-F 
Foley catheter was placed through a pursestring suture in the pyloric antrum to 
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inflate the stomach with room air.  An umbilical tape ligature was placed around 
the distal esophagus and around the proximal duodenum.  Care was taken to avoid 
the vagus nerve and gastric vessels when placing the tape ligatures.  The stomach 
was rotated 270˚ clockwise by moving the pylorus ventrally and suturing it to the 
body wall adjacent to the cranial pole of the left kidney.  The body and fundus of 
the stomach was pushed dorsally and to the right to facilitate rotation.  The greater 
omentum was seen covering the stomach and the duodenum was positioned 
adjacent to the esophagus.  An air compressor was connected to the Foley catheter 
and the stomach was inflated with air until an intragastric pressure of 30 mm Hg 
was reached, documented by connecting the catheter to a transducer. 
     In GDV dogs, the intragastric pressure was maintained for 120 minutes.  At 
120 minutes, the stomach was then decompressed, repositioned and the umbilical 
tape ligatures were cut.  The dog was then monitored for an additional 90 minutes, 
allowing for reperfusion.  In the Ischemia dogs, the intragastric pressure was 
maintained for the entire 210 minutes of monitoring.  
3.2.3 Tissue sample collection –  For all dogs, tissue from the gastric fundus, pylorus 
and jejunum were taken at 0, 120 and 210 minutes.  Mucosal tissue samples 
(1.0cm X 0.50mm) for HPLC analysis were taken, quickly rinsed with sterile 
saline until free of obvious blood contamination and then immediately placed in 
cryotubes and dropped in liquid nitrogen before being transported to a -70˚ C 
freezer for storage.  Full-thickness samples (4.0cm X 4.0 cm) were taken from the 
fundus and jejunum for Ussing chamber use and immediately placed in chilled 
Ringer’s solution that had been aerated with 95% O2/5% CO2 for 10-20 minutes. 
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The samples were then transported immediately to the laboratory for further 
preparations and mounting in the Ussing chambers.  For the purposes of 
histopathology, full-thickness samples were taken from the fundus, pylorus and 
jejunum and stored in neutral buffered 10% formalin.  The stomach and jejunum 
were sutured after samples were obtained and inflation was adjusted when 
necessary.  All dogs were euthanized after 210 minutes using Beuthanasiaa  
(2ml/10kg) solution. 
3.2.4 Hemodynamic measurements and blood sampling – Electrocardiogram, mean 
arterial pressure, portal pressure and central venous pressures were continuously 
measuredb.  Blood gas samples were obtained and analyzed at 0, 120 and 210 
minutes.  Blood sampling for packed cell volume and total protein were taken 
every 15 minutes for the duration of the study. 
3.2.5 High performance liquid chromatography – Tissue samples obtained for ATP 
quantification using HPLC were stored in a –70˚ C freezer.  These samples were 
lyophilizedc within 24 hours after collection.  The extraction method used was 
adapted from techniques previously described.13,14  On the day of analysis, frozen 
tissue samples were weighed (7-13 mg dry weight) in duplicate from the parent 
sample and placed in individual 10 ml conical tubes.  Calculations were 
performed for each sample and iced cold perchloraic acid (1 ml of 0.6 N 
HClO4/1.5 mg of tissue dry weight) was added to each sample, and the samples 
were homogenized using a tissuemizerd.  The tissuemizer was cleaned using 
HPLC water and methanol between each sample.  The samples were maintained 
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on ice, capped and centrifuged at -5˚ C at 2,500 RPM for 12 minutes.  Then, 
1,200 µL of each tissue extract was placed into individually labeled 5 ml conical 
glass tubes on ice and 800 µL of iced cold potassium bicarbonate was added 
dropwise to each conical tube.  The tubes were vortexed until mixed and capped.  
The samples were then centrifuged at -5˚C at 2000 RPM for 15 minutes. 
     Neutralized samples were filtered through a nylon filtere into HPLC vials.  The 
HPLC vials were loaded into auto-sampler magazines and the ATP, ADP and 
AMP were separated by HPLC using an Alltech Adsorbosphere C 18 5 µm 
columnf.  Detection was performed by a diode-array detectorg set at a peak 
wavelength of 260 nm.  The peaks were quantified by area under the curve and 
compared against peak areas of known standards of ATP, ADP and AMP. 
3.2.6 Ussing chambers – The full-thickness samples were pinned to a rubber surface, 
with the mucosal surface up and submerged in a Krebs-Ringer-bicarbonate (KRB) 
solution at room temperature.  The KRB used to bathe all tissues contained 142 
mM Na, 5 mM K, 1.25 mM Ca, 1.1 mM Mg, 124 mM Cl, 25 mM HCO3, 1.65 
HPO4, 10mM glucose and 0.3 mM H2PO4.  While the tissue was gassed 
continuously in the solution with a 95% O2-5% CO2 gas mixture, dissection was 
performed to carefully remove the mucosal layer.  These mucosal segments were 
then mounted in Ussing chambers (3.14 cm2 exposed surface area).  The tissue 
was bathed on both sides with 10 ml of KRB solution circulated with 95% O2 – 
5% CO2.  A temperature of 37˚ C was maintained. 
     Transepithelial short-circuit, electrical potential difference and conductance 
were monitored with an automatic voltage clamp amplifierh.  Transepithelial short 
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circuit and potential difference were measured and recorded every 15 minutes for 
180 minutes.  Tissue conductance was calculated as the ratio of short-circuit 
current to open circuit PD.  Resistance was calculated using Ohm’s law. 
3.2.7 Histopathology – Tissue samples were stored in neutral buffered 10% formalin 
until they were routinely processed with paraffin and stained with hematoxylin 
and eosin stain. 
3.2.8 Statistical method 
Hemodynamic data – All variables were considered continuous and followed a 
normal distribution as noted by failure to reject the null hypothesis of normality at 
p≤0.05 using the Shapiro-Wilk test.  The data was summarized as mean +/- SEM.  
The data was evaluated for an effect of treatment and time using a mixed linear 
model accounting for the random variance of dog and the repeated measurements 
on each dog.  Where there were significant interaction effects at p≤ 0.05, 
predetermined multiple comparisons were made across time within each treatment 
group, and between groups at specified time periods using least squares means 
maintaining type I error at 0.05.  Thus, where a difference is noted, unless 
specified, p ≤ 0.05. 
ATP concentration – The concentration of ATP ADP and AMP was considered 
continuous and followed a normal distribution as noted by failure to reject the null 
hypothesis of normality at p ≤ 0.05 using the Shapiro-Wilk test.  The data was 
summarized as mean +/- SEM.  The data was evaluated for an effect of treatment 
and time using mixed linear model accounting for the random variance of dog and 
the repeated measurements on each dog.  Where there were significant interaction 
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effects at p ≤ 0.05, predetermined multiple comparisons were made across time 
within each treatment group using least squares means maintaining type I error at 
0.05 to describe the behavior of the ATP concentration over time.  Treatments 
that behaved differently over time were thus implied to be different.  Where 
treatments behaved the same, comparisons were made if it was necessary to 
determine if there was a difference in the proportional magnitude of change 
between treatments.  The proportional magnitude of change was compared using 
least squares means maintaining type I error at 0.05.  Thus, where a difference is 
noted for any result, unless specified, p ≤ 0.05. 
Conductance – For the purpose of analysis, the standardized conductance was 
over time (180 minutes) was plotted for each tissue sample and the area under the 
curve (conductance time) was calculated using the trapezoid method.15 The 
standardized conductance time thus reflected the magnitude of the conductance 
over the time of evaluation in the Ussing chamber.  The standardized 
conductance-time was considered continuous and followed a normal distribution 
as noted by failure to reject the null hypothesis of normality at p ≤ 0.05 using the 
Shapiro-Wilk test.  The conductance-time data was summarized as mean +/- 
SEM.  The data was evaluated for an effect of treatment and time using a mixed 
linear model accounting for the random variance of dog and the repeated 
measurements on each dog.  Where there were significant interaction effect at p ≤ 
0.05, predetermined multiple comparisons were made across time within each 
treatment group, and between groups at specified time periods using least squares 
 51  
means maintaining type I error at 0.05.  Thus, where a difference is noted, unless 
specified, p ≤ 0.05. 
      PROC UNIVARIATE, PROC MEANS AND PROC MIXEDi was used. 
3.3      RESULTS 
3.3.1 HPLC 
Adenosine triphosphate findings – Adenosine triphosphate was compared within 
tissue groups (fundus, pylorus and jejunum) and among tissue groups at baseline.  
(Appendix 1) 
Fundus – Concentrations of ATP in the fundus did not change significantly over 
time in the GDV dogs.  A significant increase in ATP was seen between 120 and 
210 minutes in the fundus in the Control dogs.  The ATP in the fundus decreased 
significantly from baseline to 210 minutes in the Ischemia dogs.  (figure 3.1) 
A significant increase in ADP was seen between baseline and 120 minutes in the 
Control dogs.  A decrease in ADP was seen in this group between 120 and 210 
minutes, but the decrease was not significant.  No significant difference in ADP 
was seen over time in the GDV or Ischemia dogs.  (Figure 3.2) 
A significant decrease in AMP was seen in the GDV dogs between baseline and 
120 minutes.  No significant change was seen in AMP between 120 and 210 
minutes in the GDV dogs.  No significant difference in AMP content was seen 
over time in the Control or Ischemia dogs.  (Figure 3.3) 
Pylorus – No difference was seen in ATP over time in the GDV or Control dogs.  
A significant decrease in ATP was seen between baseline and 120 minutes in the 
Ischemia dogs, but returned to baseline concentrations at 210 minutes.  (Figure 
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3.1)  A significant increase in ADP was seen between 120 and 210 minutes.  No 
significant differences in ADP over time were seen in the Ischemia or Control 
dogs.  (Figure 3.2)  A significant increase in AMP was seen between 120 and 210 
minutes in the GDV dogs.  No significant difference in AMP was seen over time 
in the Ischemia or Control dogs.  (Figure 3.3) 
Jejunum – Concentrations of ATP in the jejunum did not change significantly 
over time in the Control dogs.  A significant decrease in ATP was seen between 
baseline and 120 minutes in both the GDV and Ischemia dogs.  The concentration 
of ATP remained significantly decreased in the Ischemia dogs at 210 minutes.  An 
increase in ATP to baseline concentrations was seen in the GDV dogs at 210 
minutes.  (Figure 3.1)  No significant difference was seen over time in 
concentrations of ADP or AMP in any of the dogs. (Figures 3.2 and 3.3) 
Baseline – Collectively, at baseline, the ATP content was greater in the jejunum 
compared to the fundus, but equal between the fundus and pylorus, and jejunum 
and pylorus. 
At baseline, the ADP content was greatest in jejunum, followed in content by 
pylorus and fundus. 
At baseline, the AMP content was greater in the jejunum compared to the pylorus, 
but equal between the fundus and pylorus, and the jejunum and fundus. 
3.3.2 Ussing chambers – Comparisons in tissue conductance were made within each 
tissue group.  (Appendix 2 and 3) 
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Stomach – No significant difference in conductance-time was seen in the Control, 
GDV and Ischemia dogs from baseline to 120 minutes to 210 minutes.  (Figure 
3.4) 
Jejunum – The conductance-time in the jejunum did not change significantly 
over time in the Control dogs.  The conductance-time increased significantly 
above baseline at 120 minutes in both the Ischemia and GDV dogs and remained 
significantly increased above baseline at 210 minutes in the Ischemia dogs.  The 
conductance-time continued to further increase significantly above baseline at 210 
minutes in the GDV dogs. 
Baseline – When conductance-time was compared between groups as an absolute 
value, conductance-time was greatest in the GDV dogs, followed by the Ischemia 
dogs and the Control dogs.  (Figures 3.4) 
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Figure 3.1 – Concentration of ATP (µg/ml) in the fundus, pylorus and jejunum  
over 210 minutes in Control, Ischemia and GDV dogs (mean +/- 
SEM).  Those points with same letters are not significantly 
different. 
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Figure 3.2 – Concentration of ADP (µg/ml) in the fundic, pyloric and jejunal 
mucosa over 210 minutes in Control, Ischemia and GDV dogs 
(mean +/- SEM).  Those points with same letters are not 
significantly different. 
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Figure 3.3 – Concentration of AMP (µg/ml) in the fundic, pyloric and jejunal mucosa 
over 210 minutes in Control, Ischemia and GDV dogs (mean +/- SEM).  
Those points with same letters are not significantly different. 
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Figure 3.4 –Fundic and jejunal mucosal conductance (mean +/- SEM, ∆G) 





No cardiac arrhythmias were seen in any dogs during the 210 minutes.  
Hemodynamic changes in the GDV and Ischemia dogs included a decreased mean 
arterial pressure, profoundly increased portal pressure, with improvements noted 
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after decompression and derotation of the stomach in the GDV dogs.  (Figures 
3.5)  (Appendix 4) 
 
Figure 3.5 – Arterial pressure (mean +/- SEM, mm Hg) and portal pressure (mean +/- 
  SEM, mm Hg) recorded every 15 minutes for 210 minutes 
 
3.3.4 PCV/TP – No profound changes were seen in Control dogs over 210 minutes.  
Transient increases and decreases in PCV were seen in Ischemia and Control 
dogs.  The changes were similar in degree in the TP.  (Figure 3.6)  (Appendix 5) 
3.3.5 Blood gas – No appreciable difference was seen between groups in blood gas 
parameters.  A mild metabolic acidosis was seen in dogs, but arterial pH, pO2 and 
pCO2 were within normal limits for anesthetized dogs.  (Appendix 6) 
3.3.6 Histopathology – During periods of gastric dilatation and volvulus, the gross 
pathology was similar in both the GDV and Ischemia dogs with varying degrees 
of edema and hyperemia of the stomach and small intestine.  Severe cyanosis was 
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also appreciated in the small intestine.  After decompression and derotation of 
GDV dogs, incomplete resolution of hyperemia was seen. 
Microscopically, no lesions were seen in the Control dogs.  Mild to moderate 
edema and congestion was noted in all layers, especially the mucosa, of the 
gastric tissue and jejunum in both GDV and Ischemia dogs.  No differences were 
seen between the character and severity of histologic lesions between groups, 
except for the jejunum, in which severe conjestion was noted primarily in the 
mucosal layer (lamina propria).  Histopathology was performed on mucosal tissue 
used in the Ussing chambers.  Lesions seen were similar to other treatment groups 
and included loss of glands, crypts and villous epithelium in the jejunum. (Figures 
3.7 and 3.8) 
 
Figure 3.6 – Mean (+/- SEM) pack cell volume (%) and total protein (g/dL) of Control, 
  Ischemia and GDV dogs recorded every 15 minutes for 210 minutes 
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Figure 3.7 --  Histopathology of gastric mucosa 
 
 
Figure 3.8 – Histopathology of jejunal mucosa 
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3.4 DISCUSSION 
     Complications are common with GDV and death within the first four days after 
surgical correction have been attributed to gastric necrosis, reperfusion injury and cardiac 
arrhythmias.16-21 
     Tissues in GDV are subject to a profound decrease in surface oxygen tension 
suggestive of gastric ischemia.9  Because the mucosa requires 75-80% of the total 
gastrointestinal blood flow, the effects of ischemia and reperfusion are most profound in 
the gastric mucosa.7  Ischemia can therefore be implicated as the primary contributor to 
ATP depletion that leads to inadequate energy production and undesirable tissue changes, 
such as cellular edema, infarction and gastric necrosis.7   
     High performance liquid chromatography (HPLC) is a process that possesses the 
ability to precisely detect, separate and quantify substances.22 To our knowledge, quantity 
of ATP and a description of cellular permeability of the gastric and jejunal mucosa with 
GDV have not been done.  Results of this study suggest that the concern for 
complications associated with necrosis of the mucosa during GDV could be extended to 
the jejunum.  Decreases in ATP were seen between 0 and 120 minutes in the jejunum in 
both the GDV and Ischemia dogs; however, as expected, ATP content showed a 
significant increase from 120 to 210 minutes after decompression and derotation in the 
GDV dogs, suggesting metabolic recovery of the mucosa. 
     An unexpected finding was the significant increase in ATP concentration was seen in 
the fundic mucosa in the Control dogs.  We hypothesized that it was possible that since a 
substantial amount of blood was extravasated after biopsies, absorption of intraluminal 
gastric blood could have been an addition source of ATP and could have falsely elevated 
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the ATP concentration.  If this theory was accepted, then it could be extrapolated that 
actual ATP concentrations of the fundic mucosa in the Control, Ischemia and GDV dogs 
were, in fact, lower than the measurements reflected. 
     Ussing chambers were used to examine mucosal permeability.  Total tissue 
conductance (Gt) is calculated using Ohm’s law and reflects the contribution of both 
active and passive ion movements.23  Total tissue conductance is directly related to the 
permeability of tissue and can be indicative of mucosal function and viability.24  
     Interestingly, increases in permeability were only seen in jejunal mucosa in the GDV 
and Ischemia dogs and not the gastric fundus.  This observation could suggest greater 
loss of integrity in the jejunal mucosa in the acute stages of injury induced by GDV.  The 
greater increase appreciated in conductance in the GDV dogs is suggestive of further 
injury by a 90-minute reperfusion period.  It has been demonstrated that superoxide 
radicals produced during periods of reintroduction of molecular oxygen are responsible 
for an increase in a breakdown in lipid membranes, an increase in permeability and more 
severe injury than that produced by ischemia alone.25-27   
     The experimental model used in this study was designed to mimic the acute phase of 
clinical GDV.  The decision to maintain intragastric pressure at 30 mm Hg, apply 270 
degrees of volvulus and the duration of the ischemic time periods were based upon 
previous experiments.6  Although changes in ATP content and cellular permeability were 
not seen in the fundus, assessment of changes in the microscopic features, conductance 
and hemodynamic parameters, supported that the experimental model was severe enough 
to mimic changes seen in spontaneous GDV.     The microscopic changes in the stomach 
and jejunum showed edema and congestion primarily in the mucosal layer.  The edema 
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and congestion were more severe in the jejunal mucosa, which could suggest that the 
jejunum could contribute substantially to the complications associated with GDV such as 
mucosal necrosis and translocation of bacteria into the systemic circulation.   
     Changes in mean arterial pressure, portal pressure and heart rate resolved after 
decompression and repositioning of the stomach.  With decompression and the 
restoration of normal anatomy, splanchnic blood flow and venous return could be re-
established. Changes in packed cell volume, total protein and blood gas were similar to 
changes reported in other cases of experimentally-induced GDV.7  The decreases seen in 
both PCV and TP could be attributed to hemodilution and loss from the gastrointestinal 
system during GDV. 
     Changes in ADP and AMP during the experimental model were variable and did not 
follow any patterns that could be associated with ATP activity.  The alterations in tissue 
perfusion were severe enough during the periods of ischemia that the changes could 
possibly be a direct result of ATP, ADP and AMP utilization by the breaking of 
phosphate bonds.  In an attempt to meet metabolic demands, it could be expected that 
synthesis of ATP and its metabolites would occur.  The trends did not specifically 
support either theory; consequently, it is difficult to interpret whether the ADP and AMP 
we measured were in the process of synthesis or breakdown. 
     While there was an expected decrease in ATP concentration occurred in the fundus of 
the Ischemia dogs, this was only after 210 minutes of volvulus and was surprisingly not 
observed in the GDV dogs.  The gastric mucosa of GDV and Ischemia dogs also did not 
show permeability changes expected by the authors.  The jejunum, however, did show 
changes in both concentrations of ATP and conductance suggestive of damage to both 
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cellular function and cellular permeability.  The further increase in permeability in the 
jejunum in the GDV dogs after decompression and derotation of the stomach suggests 
that despite the recovery of ATP concentration, reperfusion may have incited further 
disruption of the mucosal permeability.  Based on this study, it is proposed that the loss 
of integrity of the jejunal mucosa may be a contributor to the pathophysiologic sequela of 
GDV and could be responsible in part for complications such as bacteremia and sepsis 
that are often seen post-operatively in GDV.  In the case of GDV, damage to the gastric 
tissue has been implicated as a contributor to increased morbidity and mortality.21  
However, it is the authors’ opinion that with the changes seen in ATP concentration and 
in mucosal permeability, concern for potential problems seen in GDV should be extended 
to the jejunum as a possible source of complications. 
3.5  END NOTES 
a  Beuthanasia – D Special, Schering-Plough Animal Health, Union, NJ 07083 
b  Passport Datascope 5 Lead, 5 L, XG, Paramus, NJ 
c  FreeZone 4.5 liter freeze dry system, Model 77510, Labconco Corporation, Kansas 
City, MO 
 
d  Ultra-turrax, Tekmar Corporation, Cincinnati, OH 
 
e  Nalgene 4 mm syringe filters #176-0045, Nalge Company, Rochester, NY 
 
f  Adsorbosphere C18 5U column, Direct-connect prefilter kit #28689, All-guard 
cartridge system #96041, Alltech Associates, Deerfield, IL 
 
g  HP 1090 liquid chromatograph, Agilent technologies, Wilmington, DE 
 
h  DVC – 1000, World Precision Instruments, New Haven, CT 
 
i  SAS Vs 8.2, SAS Institute, Cary, NC 
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SUMMARY 
     Adensosine triphosphate has been embraced as a physiologic cornerstone of tissue 
metabolism and appears to be a critical contributor to the health and integrity of 
mammalian tissues.  With tissue hypoxia, it seems logical that concentrations of this ATP 
would be compromised in tissue; however, the exact method for measuring ATP and its 
metabolites during GDV has not been pursued.  Therefore, in order to appreciate ATP 
and its relationship to ischemia, subsequent hypoxia and reperfusion, a method for ATP 
quantification needed to be pursued and examined.  Because HPLC is an accurate and 
relatively simple means of separation, analysis and quantification of complex substances, 
it appears to provide an accurate representation of ATP in the mucosal tissue during 
various physiologic and metabolic challenges seen with acute GDV.  Coupled with the 
changes seen in ATP, the Ussing chambers provided an interesting and useful 
complement to quantification of ATP and an ostensible relationship with increased tissue 
permeability. 
     The potential for complications associated with GDV have implications in the 
management before, during and after the disease process has occurred.  An increase in 
morbidity and mortality has been associated with translocation of bacteria, tissue necrosis 
and sepsis resulting from compromise in gastrointestinal tissue.  Because the jejunal 
mucosa was the tissue most profoundly affected both on a cellular function level and as a 
function of permeability, it may be a contributor to life-threatening complications seen 
primarily during surgery and in the first hours to days after surgery.  The dogs in which 
GDV was created showed classic systemic signs associated with acute spontaneous GDV.  
Also, grossly and microscopically confirmed that the severity of the model supported 
 69  
 70  
concern for potentially irreversible damage to the jejunum.  These results should not 
necessarily redirect attention away from the stomach as a potential source of 
complication, but rather, attention should be given to a full exploration of the abdominal 
cavity with evaluation of the abdominal organs during surgery. 
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Time Site Treatment Mean Std. Error N 
0 F Control 2.5850000 0.3154300 10 
120 F Control 3.0110000 0.2272123 10 
210 F Control 3.7330000 0.3002260 10 
0 F GDV 2.1986000 0.4910444 10 
120 F GDV 2.3400000 0.2727473 10 
210 F GDV 2.6460000 0.2577173 10 
0 F Ischemia 1.9000000 0.2662747 10 
120 F Ischemia 1.2471000 0.2731530 10 
210 F Ischemia 1.1679000 0.1761541 10 
0 J Control 3.0360000 0.4849449 10 
120 J Control 2.7390000 0.3124969 10 
210 J Control 2.8800000 0.2318333 10 
0 J GDV 2.3140000 0.1919213 10 
120 J GDV 1.2602000 0.3204911 10 
210 J GDV 2.4630000 0.2272837 10 
0 J Ischemia 2.5350000 0.2378013 10 
120 J Ischemia 1.5179000 0.5092890 10 
210 J Ischemia 1.8107000 0.4885400 10 
0 P Control 2.4020000 0.2618982 10 
120 P Control 2.5912000 0.3270394 10 
210 P Control 2.9933333 0.3402450 9 
0 P GDV 2.2020000 0.2211525 10 
120 P GDV 2.2380000 0.2943309 10 
210 P GDV 2.3240000 0.2719975 10 
0 P Ischemia 2.4350000 0.1522297 10 
120 P Ischemia 1.5677000 0.1998547 10 



















Time Site Treatment Mean Std. Error N 
0 F Control 0.6409000 0.0822177 10 
120 F Control 1.3953000 0.6725764 10 
210 F Control 0.9994000 0.1118890 10 
0 F GDV 0.7052000 0.0888148 10 
120 F GDV 0.6072000 0.0691610 10 
210 F GDV 0.9510000 0.1010941 10 
0 F Ischemia 0.4417500 0.0691373 10 
120 F Ischemia 0.4744000 0.0382068 10 
210 F Ischemia 0.5119000 0.0226679 10 
0 J Control 1.4594000 0.1302985 10 
120 J Control 1.5298000 0.1466386 10 
210 J Control 1.4650000 0.0964394 10 
0 J GDV 1.4290000 0.1111900 10 
120 J GDV 1.2114000 0.1016823 10 
210 J GDV 1.4550000 0.0767138 10 
0 J Ischemia 1.0882000 0.0830819 10 
120 J Ischemia 0.8192000 0.1553076 10 
210 J Ischemia 0.9046000 0.0765965 10 
0 P Control 0.8370000 0.0691093 10 
120 P Control 0.7173000 0.0623943 10 
210 P Control 0.9157778 0.1326300 9 
0 P GDV 0.8823000 0.0903314 10 
120 P GDV 0.8855000 0.1163941 10 
210 P GDV 1.7084000 0.4941539 10 
0 P Ischemia 0.6969000 0.0681933 10 
120 P Ischemia 0.5828000 0.0493835 10 



















Time Site Treatment Mean Std. Error N 
0 F Control 0.3481778 0.0806515 9 
120 F Control 0.5038750 0.2182637 8 
210 F Control 0.2032400 0.0487767 10 
0 F GDV 0.8035400 0.4894855 10 
120 F GDV 0.2566000 0.0465341 10 
210 F GDV 0.3191000 0.0349744 10 
0 F Ischemia 0.2050000 0.0309031 9 
120 F Ischemia 0.4855000 0.0649446 10 
210 F Ischemia 0.3373000 0.0630016 10 
0 J Control 0.5670000 0.0645568 10 
120 J Control 0.6504000 0.0933009 10 
210 J Control 0.4438000 0.0633789 10 
0 J GDV 0.7201000 0.1119242 10 
120 J GDV 0.9221000 0.0815759 10 
210 J GDV 0.7204000 0.0744803 10 
0 J Ischemia 0.6645000 0.0742801 10 
120 J Ischemia 0.6717000 0.0540344 10 
210 J Ischemia 0.6695000 0.0937685 10 
0 P Control 0.2536000 0.0257855 10 
120 P Control 0.3426000 0.0698709 10 
210 P Control 0.3463333 0.0622075 9 
0 P GDV 0.3660000 0.0337941 10 
120 P GDV 0.3662000 0.0563163 10 
210 P GDV 0.6851000 0.1186381 10 
0 P Ischemia 0.3416000 0.0510780 10 
120 P Ischemia 0.4923000 0.0903674 10 























0 SI CONTROL 0 1.0000000 0 
0 SI CONTROL 30 0.8585906 0.0594815 
0 SI CONTROL 60 0.7039889 0.0610391 
0 SI CONTROL 90 0.6019971 0.0540363 
0 SI CONTROL 120 0.5247983 0.0532361 
0 SI CONTROL 150 0.4926970 0.0535659 
0 SI CONTROL 180 0.4803848 0.0565914 
0 SI GDV 0 1.0000000 0 
0 SI GDV 30 0.8733374 0.0296381 
0 SI GDV 60 0.8182957 0.0361011 
0 SI GDV 90 0.7442887 0.0411231 
0 SI GDV 120 0.6701390 0.0441424 
0 SI GDV 150 0.6159132 0.0461034 
0 SI GDV 180 0.5852307 0.0527911 
0 SI ISCHEMIA 0 1.0000000 0 
0 SI ISCHEMIA 30 0.7312120 0.0571415 
0 SI ISCHEMIA 60 0.7505791 0.0640081 
0 SI ISCHEMIA 90 0.7235509 0.0745519 
0 SI ISCHEMIA 120 0.6987197 0.0788778 
0 SI ISCHEMIA 150 0.6962826 0.0718077 
0 SI ISCHEMIA 180 0.6752603 0.0729384 
0 STO CONTROL 0 1.0000000 0 
0 STO CONTROL 30 0.8703703 0.0667694 
0 STO CONTROL 60 0.8180417 0.1014109 
0 STO CONTROL 90 0.8089223 0.1025174 
0 STO CONTROL 120 0.8087823 0.1210109 
0 STO CONTROL 150 0.8591473 0.1402707 
0 STO CONTROL 180 0.9187710 0.1617318 
0 STO GDV 0 1.0000000 0 
0 STO GDV 30 0.7552535 0.0986291 
0 STO GDV 60 0.6928700 0.1212218 
0 STO GDV 90 0.6807750 0.1286880 
0 STO GDV 120 0.7154278 0.1444939 
0 STO GDV 150 0.7713833 0.1870013 
0 STO GDV 180 0.8257815 0.2275271 
0 STO ISCHEMIA 0 1.0000000 0 
0 STO ISCHEMIA 30 0.9132620 0.0331854 
0 STO ISCHEMIA 60 0.9277130 0.0836871 
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0 STO ISCHEMIA 90 0.9082570 0.0723573 
0 STO ISCHEMIA 120 0.9314090 0.0709604 
0 STO ISCHEMIA 150 0.9442513 0.0796884 
0 STO ISCHEMIA 180 0.9184868 0.0817107 
120 SI CONTROL 0 1.4576287 0.2447821 
120 SI CONTROL 30 1.1489551 0.1978942 
120 SI CONTROL 60 1.0802293 0.2294820 
120 SI CONTROL 90 1.0039735 0.2205894 
120 SI CONTROL 120 0.9292180 0.2074405 
120 SI CONTROL 150 0.9145848 0.2027560 
120 SI CONTROL 180 0.8342729 0.1984663 
120 SI GDV 0 1.2277200 0.1581007 
120 SI GDV 30 1.1312372 0.1567788 
120 SI GDV 60 1.1130006 0.1727334 
120 SI GDV 90 1.1657559 0.2017113 
120 SI GDV 120 0.9780661 0.1820998 
120 SI GDV 150 0.9465991 0.1899823 
120 SI GDV 180 0.9178546 0.1825739 
120 SI ISCHEMIA 0 1.1386265 0.2393975 
120 SI ISCHEMIA 30 1.1783978 0.2364189 
120 SI ISCHEMIA 60 1.1525389 0.2257148 
120 SI ISCHEMIA 90 1.1694499 0.2337511 
120 SI ISCHEMIA 120 1.1773255 0.2412221 
120 SI ISCHEMIA 150 1.1799145 0.2420018 
120 SI ISCHEMIA 180 1.1577403 0.2497976 
120 STO CONTROL 0 1.7595397 0.6794778 
120 STO CONTROL 30 1.2255890 0.3812834 
120 STO CONTROL 60 1.1627387 0.4244134 
120 STO CONTROL 90 1.3626543 0.7141361 
120 STO CONTROL 120 1.5526093 0.9725094 
120 STO CONTROL 150 1.6947247 1.1377865 
120 STO CONTROL 180 1.7932097 1.2356439 
120 STO GDV 0 0.7517560 0.0796957 
120 STO GDV 30 0.5346808 0.0811687 
120 STO GDV 60 0.4867123 0.0786212 
120 STO GDV 90 0.5126290 0.1324572 
120 STO GDV 120 0.4973835 0.0641562 
120 STO GDV 150 0.5402400 0.0633805 
120 STO GDV 180 0.5726685 0.0752039 
120 STO ISCHEMIA 0 1.3344353 0.4264463 
120 STO ISCHEMIA 30 1.0525093 0.3820015 
120 STO ISCHEMIA 60 1.1315315 0.4961696 
120 STO ISCHEMIA 90 1.1079055 0.5046962 
120 STO ISCHEMIA 120 1.0877655 0.5101424 
120 STO ISCHEMIA 150 1.1165423 0.5011561 
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120 STO ISCHEMIA 180 1.1302585 0.4976864 
210 SI CONTROL 0 1.2151096 0.2326912 
210 SI CONTROL 30 1.0913956 0.2305036 
210 SI CONTROL 60 1.0310661 0.2323506 
210 SI CONTROL 90 0.9801501 0.2378057 
210 SI CONTROL 120 0.9288061 0.2461780 
210 SI CONTROL 150 0.9024785 0.2403434 
210 SI CONTROL 180 0.8975634 0.2528857 
210 SI GDV 0 2.2677209 0.7618364 
210 SI GDV 30 2.2506070 0.6901641 
210 SI GDV 60 2.2151980 0.8044014 
210 SI GDV 90 1.9359208 0.6182346 
210 SI GDV 120 1.8423839 0.6217505 
210 SI GDV 150 2.0489820 0.7941652 
210 SI GDV 180 1.8137551 0.6155075 
210 SI ISCHEMIA 0 1.9062805 0.8455776 
210 SI ISCHEMIA 30 1.8572919 0.8399076 
210 SI ISCHEMIA 60 1.9650649 0.9386371 
210 SI ISCHEMIA 90 2.0934310 1.0438597 
210 SI ISCHEMIA 120 2.1737164 1.0450192 
210 SI ISCHEMIA 150 2.1576963 1.0326366 
210 SI ISCHEMIA 180 2.2696858 1.1805791 
210 STO CONTROL 0 1.037373 0.2892685 
210 STO CONTROL 30 0.8919753 0.1870532 
210 STO CONTROL 60 0.7728673 0.1600368 
210 STO CONTROL 90 0.7327443 0.1511223 
210 STO CONTROL 120 0.9128787 0.2698190 
210 STO CONTROL 150 1.2549100 0.6172535 
210 STO CONTROL 180 1.3721943 0.7237733 
210 STO GDV 0 1.0645063 0.3168432 
210 STO GDV 30 0.6650500 0.1702502 
210 STO GDV 60 0.5844428 0.1449810 
210 STO GDV 90 0.5164053 0.1274487 
210 STO GDV 120 0.4973065 0.1313266 
210 STO GDV 150 0.5161633 0.1492572 
210 STO GDV 180 0.5394345 0.1571815 
210 STO ISCHEMIA 0 1.1113260 0.1784663 
210 STO ISCHEMIA 30 0.8939180 0.0422979 
210 STO ISCHEMIA 60 0.8087157 0.0138641 
210 STO ISCHEMIA 90 0.7710263 0.0207042 
210 STO ISCHEMIA 120 0.7795693 0.0428804 
210 STO ISCHEMIA 150 0.7476097 0.0326142 












SITE MEAN STD 
ERROR 
N 
0 CONTROL SI 117.3825000 9.0113036 8 
120 CONTROL SI 183.7087500 38.8127318 8 
210 CONTROL SI 179.7050000 42.6305628 8 
0 CONTROL STO 153.7333333 18.1530836 3 
120 CONTROL STO 263.2333333 126.4800555 3 
210 CONTROL STO 132.5900000 50.7100000 2 
0 GDV SI 138.4250000 6.2878830 8 
120 GDV SI 200.2625000 32.9139079 8 
210 GDV SI 406.6575000 135.5442214 8 
0 GDV STO 135.8525000 23.3411566 4 
120 GDV STO 96.6600000 12.6577414 4 
210 GDV STO 107.4500000 25.9590864 4 
0 ISCHEMIA SI 134.7688889 10.8582587 9 
120 ISCHEMIA SI 210.2437500 42.1793740 8 
210 ISCHEMIA SI 370.0600000 177.1600620 8 
0 ISCHEMIA STO 166.8000000 10.4743337 4 
120 ISCHEMIA STO 194.9700000 86.4597588 4 
210 ISCHEMIA STO 147.8666667 1.3544166 3 
  
APPENDIX 4 – Hemodynamic parameters mean and SEM 
 
Treatment Time Variable Mean Std. Error N 
Control 0 temp 99.2166667 0.8195188 6 
Control 0 hr 106.9090909 4.6738237 11 
Control 0 rr 9.1428571 1.7379322 7 
Control 0 sap 101.1333333 4.9017652 15 
Control 0 dap 61.5333333 2.8079253 15 
Control 0 map 75.3333333 3.4401919 15 
Control 0 cvp 2.9166667 0.3361622 12 
Control 0 portal 10.3333333 0.8926508 15 
Control 0 urine 93.7500000 93.7500000 4 
Control 15 temp 96.9600000 1.0161693 5 
Control 15 hr 105.8461538 8.6778868 13 
Control 15 rr 10.0000000 2.7255406 7 
Control 15 sap 82.6428571 3.3292034 14 
Control 15 dap 58.5000000 2.7848688 14 
Control 15 map 67.5000000 2.2744399 14 
Control 15 cvp 2.4166667 0.6087535 12 
Control 15 portal 15.6000000 3.3901819 15 
 83 
Control 15 urine 106.2500000 104.5899732 4 
Control 30 temp 96.2600000 1.0327633 5 
Control 30 hr 110.2307692 3.4625355 13 
Control 30 rr 11.0000000 3.0000000 4 
Control 30 sap 85.7333333 1.8554082 15 
Control 30 dap 54.6000000 3.0218254 15 
Control 30 map 66.2666667 2.1480150 15 
Control 30 cvp 3.2666667 0.5645619 15 
Control 30 portal 14.3333333 2.5591417 15 
Control 30 urine 143.3333333 143.3333333 3 
Control 45 temp 95.9400000 0.9952889 5 
Control 45 hr 113.0000000 4.3190099 13 
Control 45 rr 8.8571429 1.2233555 7 
Control 45 sap 78.3333333 5.6934939 15 
Control 45 dap 55.5833333 2.9270378 12 
Control 45 map 64.8666667 1.8487233 15 
Control 45 cvp 3.8666667 0.6891449 15 
Control 45 portal 14.1333333 2.3560796 15 
Control 45 urine 162.5000000 102.7436129 4 
Control 60 temp 95.3800000 1.0509044 5 
Control 60 hr 113.9090909 5.1846882 11 
Control 60 rr 9.2000000 2.3323808 5 
Control 60 sap 83.7333333 1.1729761 15 
Control 60 dap 54.3333333 3.0886377 15 
Control 60 map 65.9333333 2.2979632 15 
Control 60 cvp 2.7333333 0.5560633 15 
Control 60 portal 11.5333333 1.2978615 15 
Control 60 urine 172.5000000 100.8608778 4 
Control 75 temp 94.6800000 1.3443958 5 
Control 75 hr 112.6363636 4.4339039 11 
Control 75 rr 9.6000000 2.3151674 5 
Control 75 sap 82.9333333 1.8086213 15 
Control 75 dap 53.6666667 3.3674445 15 
Control 75 map 65.8000000 2.4692393 15 
Control 75 cvp 2.4000000 0.6817345 15 
Control 75 portal 11.2666667 1.3886158 15 
Control 75 urine 181.2500000 97.5614123 4 
Control 90 temp 95.0200000 0.9382963 5 
Control 90 hr 114.2727273 4.4458171 11 
Control 90 rr 9.6000000 2.4819347 5 
Control 90 sap 81.9333333 2.2285307 15 
Control 90 dap 53.1333333 1.9996825 15 
Control 90 map 64.9333333 1.6603691 15 
Control 90 cvp 1.6000000 0.6078847 15 
Control 90 portal 10.7333333 1.1018023 15 
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Control 90 urine 182.5000000 97.0073021 4 
Control 105 temp 94.7600000 0.8975522 5 
Control 105 hr 113.1818182 4.2614939 11 
Control 105 rr 9.4000000 2.6758176 5 
Control 105 sap 76.8000000 2.4903624 15 
Control 105 dap 50.8666667 2.3317001 15 
Control 105 map 61.8000000 1.9765289 15 
Control 105 cvp 1.9333333 0.5645619 15 
Control 105 portal 11.4000000 1.3794409 15 
Control 105 urine 183.7500000 96.3365412 4 
Control 120 temp 94.7200000 0.7870197 5 
Control 120 hr 116.7272727 4.3108550 11 
Control 120 rr 10.6000000 1.4696938 5 
Control 120 sap 74.8000000 3.3808987 15 
Control 120 dap 50.1333333 1.6355185 15 
Control 120 map 60.6000000 1.5638780 15 
Control 120 cvp 2.2666667 0.8477795 15 
Control 120 portal 12.2666667 1.3110035 15 
Control 120 urine 191.2500000 95.6202341 4 
Control 135 temp 94.5800000 0.8206095 5 
Control 135 hr 116.6666667 5.5606326 15 
Control 135 rr 12.0000000 1.2909944 7 
Control 135 sap 70.8666667 4.3059943 15 
Control 135 dap 50.2666667 1.3538892 15 
Control 135 map 58.8666667 2.1862485 15 
Control 135 cvp 1.4000000 0.6384505 15 
Control 135 portal 10.3333333 0.8027730 15 
Control 135 urine 196.2500000 95.0301487 4 
Control 150 temp 94.4000000 0.7661593 5 
Control 150 hr 121.6153846 4.0549724 13 
Control 150 rr 10.8000000 1.3190906 5 
Control 150 sap 70.0666667 3.1129020 15 
Control 150 dap 51.2666667 0.8533780 15 
Control 150 map 59.6000000 0.7354947 15 
Control 150 cvp 1.8666667 0.5679258 15 
Control 150 portal 9.9333333 0.8421439 15 
Control 150 urine 181.6666667 64.4161815 6 
Control 165 temp 94.2200000 0.8309031 5 
Control 165 hr 119.2307692 4.1140065 13 
Control 165 rr 9.6000000 1.1661904 5 
Control 165 sap 71.6666667 2.7922796 15 
Control 165 dap 50.8000000 1.0198039 15 
Control 165 map 60.0666667 0.7956229 15 
Control 165 cvp 1.9333333 0.4924832 15 
Control 165 portal 10.0000000 1.0047506 15 
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Control 165 urine 270.0000000 210.0000000 
Control 180 temp 94.1400000 5 
Control 180 hr 4.4907312 13 
Control 180 9.8000000 1.3564660 5 







Control dap 51.0000000 1.0373960 15 
Control 180 map 59.5333333 1.0135589 15 
Control 180 cvp 1.4666667 0.4563485 15 
Control 180 portal 11.0666667 1.0577004 15 
Control 180 urine 263.3333333 124.1414963 3 
Control 195 temp 94.1800000 0.9264988 5 
Control 195 hr 120.4615385 4.5072810 13 
Control 195 rr 8.6000000 1.6613248 5 
Control 195 sap 70.4666667 3.0610715 15 
Control 195 dap 49.5333333 0.7359262 15 
Control 195 map 58.9333333 1.0577004 15 
Control 195 cvp 0.5833333 0.5429763 12 
Control 195 portal 10.3333333 1.0939952 15 
Control 195 urine 266.6666667 123.4683945 3 
Control 210 temp 94.1200000 0.9334881 5 
Control 210 hr 115.6000000 5.1341991 15 
Control 210 rr 11.4285714 1.3948399 7 
Control 210 sap 69.5333333 3.4349280 15 
Control 210 dap 46.1333333 1.1248986 15 
Control 210 map 55.6000000 1.0814452 15 
Control 210 cvp 1.3333333 0.4944132 15 
Control 210 portal 10.4666667 1.1206574 15 
Control 210 urine 240.7500000 102.4543598 4 
GDV 0 temp 104.2166667 5.2122559 6 
GDV 0 hr 97.2500000 14.8861753 8 
GDV 0 rr 21.6250000 15.0664451 8 
GDV 0 sap 89.7857143 11.9376487 14 
GDV 0 dap 62.8571429 7.9323078 14 
GDV 0 map 65.2857143 9.7858547 14 
GDV 0 cvp 2.8571429 0.6942238 14 
GDV 0 portal 7.9230769 0.7202345 13 
GDV 0 urine 96.6666667 52.3874455 3 
GDV 15 temp 98.1000000 1.2263768 5 
GDV 15 hr 105.8571429 4.7580937 7 
GDV 15 rr 10.2857143 1.0168646 7 
GDV 15 sap 85.6666667 3.0854825 12 
GDV 15 dap 55.2500000 2.6173228 12 
GDV 15 map 65.4000000 2.2206820 15 
GDV 15 cvp 1.2666667 0.7956229 15 
GDV 15 portal 26.7333333 2.2242530 15 
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GDV 15 urine 106.6666667 62.2718056 3 
GDV 30 temp 97.1800000 1.2717704 5 
GDV 30 hr 114.4545455 4.8996524 11 
GDV 30 rr 7.1111111 0.8407081 9 
GDV 30 sap 86.8000000 3.7419119 15 
GDV 30 dap 58.4666667 1.5239881 15 
GDV 30 map 67.7333333 1.9259300 15 
GDV 30 cvp 1.7333333 0.6284271 15 
GDV 30 portal 28.0666667 2.1788303 15 
GDV 30 urine 95.0000000 52.3609269 4 
GDV 45 temp 97.8400000 2.4061588 5 
GDV 45 hr 117.7777778 4.0234651 9 
GDV 45 rr 8.0000000 0.7264832 9 
GDV 45 sap 92.3333333 4.5843073 15 
GDV 45 dap 60.5333333 0.6822000 15 
GDV 45 map 70.6666667 1.5604232 15 
GDV 45 cvp 1.8666667 0.5509011 15 
GDV 45 portal 25.9333333 2.3794090 15 
GDV 45 urine 165.0000000 95.0000000 2 
GDV 60 temp 95.2600000 0.5334791 5 
GDV 60 hr 125.8888889 4.7035579 9 
GDV 60 rr 8.0000000 0.5773503 9 
GDV 60 sap 91.2666667 3.5475903 15 
GDV 60 dap 59.4000000 0.6604472 15 
GDV 60 map 70.8000000 1.1305287 15 
GDV 60 cvp 2.2666667 0.6052679 15 
GDV 60 portal 22.5333333 1.5364358 15 
GDV 60 urine 136.6666667 61.7341973 3 
GDV 75 temp 94.8600000 0.6431174 5 
GDV 75 hr 125.5714286 7.9037578 7 
GDV 75 rr 8.3333333 0.8498366 9 
GDV 75 sap 90.6666667 3.2347321 15 
GDV 75 dap 58.6000000 2.7754022 15 
GDV 75 map 69.8000000 2.4459880 15 
GDV 75 cvp 2.8000000 0.6414270 15 
GDV 75 portal 25.6666667 2.2733794 15 
GDV 75 urine 122.5000000 45.8484823 4 
GDV 90 temp 94.6200000 0.7116179 5 
GDV 90 hr 124.8571429 5.4223021 7 
GDV 90 rr 8.3333333 0.5270463 9 
GDV 90 sap 87.6666667 3.3773287 15 
GDV 90 dap 58.8000000 1.8649652 15 
GDV 90 map 68.8666667 1.9514748 15 
GDV 90 cvp 1.8666667 0.7228691 15 
GDV 90 portal 27.2666667 2.0758628 15 
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GDV 90 urine 140.0000000 66.5832812 3 
GDV 105 temp 94.5800000 0.6916647 5 
GDV 105 hr 122.2857143 6.2667463 7 
GDV 105 rr 8.2222222 0.7027284 9 
GDV 105 sap 87.0000000 4.2122271 15 
GDV 105 dap 55.6666667 2.6541372 15 
GDV 105 map 66.8666667 2.8045315 15 
GDV 105 cvp 2.7333333 0.8754137 15 
GDV 105 portal 30.8666667 2.1862485 15 
GDV 105 urine 156.6666667 56.6666667 3 
GDV 120 temp 93.9600000 0.6177378 5 
GDV 120 hr 121.0000000 5.1501271 7 
GDV 120 rr 8.6666667 1.0000000 9 
GDV 120 sap 87.4000000 3.4083930 15 
GDV 120 dap 55.5333333 1.8844392 15 
GDV 120 map 67.0666667 1.5164704 15 
GDV 120 cvp 3.2666667 1.4090411 15 
GDV 120 portal 27.1333333 2.7288000 15 
GDV 120 urine 132.0000000 45.0998891 5 
GDV 135 temp 93.1400000 0.7711031 5 
GDV 135 hr 117.0000000 4.4924179 11 
GDV 135 rr 10.3333333 0.8164966 9 
GDV 135 sap 79.1333333 3.5481272 15 
GDV 135 dap 41.2666667 1.8528399 15 
GDV 135 map 56.6000000 2.4819347 15 
GDV 135 cvp 4.4666667 1.8253941 15 
GDV 135 portal 11.0666667 2.0364925 15 
GDV 135 urine 157.5000000 48.0234318 4 
GDV 150 temp 92.7000000 0.7602631 5 
GDV 150 hr 114.0000000 3.1449816 11 
GDV 150 rr 10.0000000 0.7453560 9 
GDV 150 sap 77.0666667 5.2148749 15 
GDV 150 dap 40.7333333 2.1145002 15 
GDV 150 map 55.2000000 3.3426536 15 
GDV 150 cvp 3.4666667 1.4536216 15 
GDV 150 portal 9.8000000 1.3244945 15 
GDV 150 urine 137.5000000 62.5000000 4 
GDV 165 temp 93.0250000 0.7951677 4 
GDV 165 hr 114.0000000 2.7568098 11 
GDV 165 rr 8.5555556 0.9145599 9 
GDV 165 sap 78.0666667 4.9689193 15 
GDV 165 dap 41.0000000 2.0000000 15 
GDV 165 map 55.5333333 3.1726010 15 
GDV 165 cvp 2.5333333 0.9703542 15 
GDV 165 portal 7.4666667 0.5679258 15 
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GDV 165 urine 137.5000000 62.5000000 4 
GDV 180 temp 92.6600000 0.6592420 5 
GDV 180 hr 116.2727273 2.9204324 11 
GDV 180 rr 10.5000000 0.5000000 8 
GDV 180 sap 83.1333333 4.2960299 15 
GDV 180 dap 45.7333333 2.1722638 15 
GDV 180 map 59.9333333 2.9284592 15 
GDV 180 cvp 3.4666667 1.2144631 15 
GDV 180 portal 8.7333333 0.5729345 15 
GDV 180 urine 156.6666667 92.4361642 3 
GDV 195 temp 92.3600000 0.6845436 5 
GDV 195 hr 117.1818182 2.8819759 11 
GDV 195 rr 10.8888889 0.5879447 9 
GDV 195 sap 82.8666667 4.2064199 15 
GDV 195 dap 47.6000000 2.2313780 15 
GDV 195 map 60.7333333 2.7731135 15 
GDV 195 cvp 3.0000000 1.0141851 15 
GDV 195 portal 8.1333333 0.5844547 15 
GDV 195 urine 275.0000000 125.0000000 2 
GDV 210 temp 92.6833333 0.4989433 6 
GDV 210 hr 116.0000000 2.3316011 11 
GDV 210 rr 10.8571429 1.0101525 7 
GDV 210 sap 78.7333333 4.9775368 15 
GDV 210 dap 45.4666667 2.7823708 15 
GDV 210 map 57.8000000 3.4684977 15 
GDV 210 cvp 3.5833333 1.3168968 12 
GDV 210 portal 7.9333333 0.7651123 15 
GDV 210 urine 211.2500000 63.5863914 4 
Ischemia 0 temp 100.3200000 0.5894065 5 
Ischemia 0 hr 98.0000000 8.6197448 5 
Ischemia 0 rr 19.0000000 9.0443352 5 
Ischemia 0 sap 89.6428571 4.2679577 14 
Ischemia 0 dap 58.0000000 1.4862003 14 
Ischemia 0 map 68.9285714 2.0122271 14 
Ischemia 0 cvp 2.0714286 0.8285051 14 
Ischemia 0 portal 6.2857143 0.6582408 14 
Ischemia 0 urine 8.3333333 8.3333333 3 
Ischemia 15 temp 98.6250000 0.7075486 4 
Ischemia 15 hr 111.2500000 3.6371921 4 
Ischemia 15 rr 16.2500000 9.3663849 4 
Ischemia 15 sap 66.8461538 3.4730578 13 
Ischemia 15 dap 49.9230769 2.0046789 13 
Ischemia 15 map 56.3076923 2.1255003 13 
Ischemia 15 cvp 1.0000000 1.1657506 13 
Ischemia 15 portal 29.4615385 1.7306268 13 
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Ischemia 15 urine 25.0000000 2.8867513 3 
Ischemia 30 temp 97.7000000 0.5205766 5 
Ischemia 30 hr 119.6000000 9.1465841 5 
Ischemia 30 rr 14.2000000 4.6086874 5 
Ischemia 30 sap 76.5714286 4.2629432 14 
Ischemia 30 dap 52.7142857 5.0048642 14 
Ischemia 30 map 61.4285714 4.4975137 14 
Ischemia 30 cvp 0.2857143 0.9632167 14 
Ischemia 30 portal 29.2857143 1.8139526 14 
Ischemia 30 urine 36.6666667 11.6666667 3 
Ischemia 45 temp 96.9750000 0.6182974 4 
Ischemia 45 hr 113.7500000 5.8363088 4 
Ischemia 45 rr 11.5000000 3.5939764 4 
Ischemia 45 sap 73.9230769 4.2478675 13 
Ischemia 45 dap 48.6153846 3.9944488 13 
Ischemia 45 map 58.1538462 3.7958246 13 
Ischemia 45 cvp 0.7692308 0.7438108 13 
Ischemia 45 portal 28.5384615 1.6664694 13 
Ischemia 45 urine 41.6666667 16.6666667 3 
Ischemia 60 temp 96.8500000 0.5172040 4 
Ischemia 60 hr 121.2000000 6.3984373 5 
Ischemia 60 rr 11.8000000 2.1540659 5 
Ischemia 60 sap 74.5000000 3.3310890 14 
Ischemia 60 dap 50.5714286 1.7055639 14 
Ischemia 60 map 58.9285714 2.0040187 14 
Ischemia 60 cvp 0.0714286 0.5972859 14 
Ischemia 60 portal 36.0000000 3.7195651 14 
Ischemia 60 urine 35.0000000 20.0000000 2 
Ischemia 75 temp 96.2500000 0.5041494 4 
Ischemia 75 hr 112.5000000 3.4278273 4 
Ischemia 75 rr 9.0000000 3.3166248 4 
Ischemia 75 sap 75.5384615 2.8388680 13 
Ischemia 75 dap 48.0000000 1.7431183 13 
Ischemia 75 map 57.8461538 1.9376372 13 
Ischemia 75 cvp 0 1.0224747 12 
Ischemia 75 portal 35.2307692 2.6070758 13 
Ischemia 75 urine 35.0000000 . 1 
Ischemia 90 temp 96.0000000 0.4242641 5 
Ischemia 90 hr 117.8000000 5.8770741 5 
Ischemia 90 rr 9.8000000 1.9078784 5 
Ischemia 90 sap 74.6428571 2.1164119 14 
Ischemia 90 dap 45.2857143 1.4119917 14 
Ischemia 90 map 55.9285714 1.5062663 14 
Ischemia 90 cvp 1.5000000 1.5200678 12 
Ischemia 90 portal 33.5000000 2.7350995 14 
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Ischemia 90 urine 60.0000000 30.0000000 2 
Ischemia 105 temp 95.5250000 0.4802343 4 
Ischemia 105 hr 111.5000000 2.8722813 4 
Ischemia 105 rr 9.0000000 1.6832508 4 
Ischemia 105 sap 74.5384615 2.7887489 13 
Ischemia 105 dap 44.7692308 2.1005306 13 
Ischemia 105 map 55.5384615 2.1471967 13 
Ischemia 105 cvp 0 0.8257228 12 
Ischemia 105 portal 32.1538462 2.6670981 13 
Ischemia 105 urine 65.0000000 35.000000 2 
Ischemia 120 temp 95.3600000 0.4331282 5 
Ischemia 120 hr 117.0000000 5.7271284 5 
Ischemia 120 rr 10.4000000 1.7204651 5 
Ischemia 120 sap 72.9285714 3.1734896 14 
Ischemia 120 dap 43.7142857 2.0871890 14 
Ischemia 120 map 54.2142857 2.2609406 14 
Ischemia 120 cvp 1.2142857 0.7351353 14 
Ischemia 120 portal 31.0714286 2.5407974 14 
Ischemia 120 urine 100.0000000 . 1 
Ischemia 135 temp 95.0250000 0.5706356 4 
Ischemia 135 hr 106.5714286 5.9114785 7 
Ischemia 135 rr 10.7500000 3.6371921 4 
Ischemia 135 sap 60.0769231 1.7558019 13 
Ischemia 135 dap 33.0769231 0.8508031 13 
Ischemia 135 map 43.3846154 0.7384882 13 
Ischemia 135 cvp -0.2727273 0.9731945 11 
Ischemia 135 portal 19.3636364 1.3230318 11 
Ischemia 135 urine 115.0000000 35.0000000 2 
Ischemia 150 temp 94.7600000 0.4400000 5 
Ischemia 150 hr 109.5000000 8.9731080 6 
Ischemia 150 rr 10.0000000 3.1622777 5 
Ischemia 150 sap 64.8333333 2.5549516 12 
Ischemia 150 dap 37.1666667 1.6460850 12 
Ischemia 150 map 47.5833333 1.9007906 12 
Ischemia 150 cvp 1.5454545 0.7904387 11 
Ischemia 150 portal 20.0714286 1.3443585 14 
Ischemia 150 urine 150.0000000 . 1 
Ischemia 165 temp 94.5750000 0.6329494 4 
Ischemia 165 hr 96.6666667 2.6915506 6 
Ischemia 165 rr 7.7500000 2.8394542 4 
Ischemia 165 sap 67.4615385 3.6718181 13 
Ischemia 165 dap 39.2307692 2.2221318 13 
Ischemia 165 map 49.5384615 2.6351066 13 
Ischemia 165 cvp 0.6153846 0.6749973 13 
Ischemia 165 portal 21.3076923 1.1568337 13 
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Ischemia 165 urine 150.0000000 . 1 
Ischemia 180 temp 94.2800000 0.5053712 5 
Ischemia 180 hr 102.4285714 6.1599982 7 
Ischemia 180 rr 11.2000000 1.6248077 5 
Ischemia 180 sap 68.9285714 4.8848997 14 
Ischemia 180 dap 40.5000000 3.1998455 14 
Ischemia 180 map 51.0000000 3.6025022 14 
Ischemia 180 cvp 0.4285714 0.7009749 14 
Ischemia 180 portal 22.2142857 1.4942328 14 
Ischemia 180 urine 200.0000000 . 1 
Ischemia 195 temp 93.9750000 0.6762334 4 
Ischemia 195 hr 101.5714286 6.0822033 7 
Ischemia 195 rr 10.5000000 2.2546249 4 
Ischemia 195 sap 69.3846154 5.1210206 13 
Ischemia 195 dap 41.8461538 3.3528521 13 
Ischemia 195 map 51.4615385 3.7117543 13 
Ischemia 195 cvp 0.6153846 0.8513824 13 
Ischemia 195 portal 20.9230769 1.7374515 13 
Ischemia 195 urine 230.0000000 . 1 
Ischemia 210 temp 93.8200000 0.4872371 5 
Ischemia 210 hr 105.6250000 6.3102454 8 
Ischemia 210 rr 10.8000000 1.8547237 5 
Ischemia 210 sap 70.2857143 4.7072875 14 
Ischemia 210 dap 42.5000000 3.2745271 14 
Ischemia 210 map 52.3571429 3.6743948 14 
Ischemia 210 cvp 0.4444444 0.6034878 9 
Ischemia 210 portal 18.9090909 2.0066007 11 
Ischemia 210 urine 128.3333333 85.9424872 3 
 
APPENDIX 5 – Packed cell volume and total protein mean and SEM 
 
PCV 
Time Treatment Mean Std. Error N 
0 I 31.8000000 2.0591260 5 
15 I 30.2000000 1.6552945 5 
30 I 28.0000000 1.4832397 5 
45 I 27.8000000 2.0832667 5 
60 I 27.2000000 2.2226111 5 
75 I 25.0000000 2.2583180 5 
90 I 26.8000000 2.2226111 5 
105 I 26.6000000 2.6381812 5 
120 I 26.8000000 2.4372115 5 
135 I 27.8000000 2.6343880 5 
150 I 28.4000000 2.5416530 5 
165 I 28.8000000 2.7092434 5 
 92 
180 I 26.8000000 2.4166092 5 
195 I 27.0000000 2.8635642 5 
210 I 26.4000000 2.3151674 5 
0 C 33.6000000 2.2934690 5 
15 C 31.8000000 3.2619013 5 
30 C 32.0000000 3.4641016 5 
45 C 32.0000000 3.0166206 5 
60 C 29.6000000 2.9257478 5 
75 C 29.2000000 2.9223278 5 
90 C 28.4000000 3.1874755 5 
105 C 29.2000000 3.4117444 5 
120 C 28.4000000 2.7856777 5 
135 C 29.6000000 2.6570661 5 
150 C 28.8000000 2.6907248 5 
165 C 29.4000000 3.0757113 5 
180 C 29.2000000 3.0232433 5 
195 C 29.2000000 2.7459060 5 
210 C 30.0000000 3.0166206 5 
0 G 31.0000000 3.1464265 5 
15 G 32.2000000 0.5112729 5 
30 G 33.6000000 2.5019992 5 
45 G 33.6000000 2.5019992 5 
60 G 34.7500000 3.0923292 4 
75 G 32.2000000 4.0174619 5 
90 G 30.2000000 2.7092434 5 
105 G 30.4000000 2.8565714 5 
120 G 29.8000000 2.1307276 5 
135 G 32.4000000 1.8055470 5 
150 G 31.4000000 1.7776389 5 
165 G 29.8000000 1.1135529 5 
180 G 29.0000000 0.7745967 5 
195 G 28.8000000 0.9695360 5 
210 G 28.4000000 0.9273618 5 
 
TP 
Time Treatment Mean Std. Error N 
0 I 4.9800000 0.4152108 5 
15 I 4.3600000 0.3957272 5 
30 I 4.1600000 0.4610857 5 
45 I 3.9600000 0.4319722 5 
60 I 3.7400000 0.4822862 5 
75 I 3.8000000 0.5319774 5 
90 I 3.7000000 0.4277850 5 
105 I 3.5600000 0.4512206 5 
120 I 3.5800000 0.4554119 5 
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135 I 3.2200000 0.4152108 5 
150 I 3.3400000 0.4166533 5 
165 I 3.3000000 0.4560702 5 
180 I 3.4000000 0.4427189 5 
195 I 3.1400000 0.3515679 5 
210 I 2.9800000 0.3733631 5 
0 C 5.1800000 0.3231099 5 
15 C 4.9800000 0.4328972 5 
30 C 4.7600000 0.4770744 5 
45 C 4.6400000 0.5316014 5 
60 C 4.5400000 0.5784462 5 
75 C 4.4800000 0.5678028 5 
90 C 3.9600000 1.0279105 5 
105 C 4.4000000 0.6760178 5 
120 C 4.4000000 0.6131884 5 
135 C 4.2800000 0.6974238 5 
150 C 4.2600000 0.6637771 5 
165 C 4.2600000 0.6764614 5 
180 C 4.2000000 0.6387488 5 
195 C 3.8200000 1.0106434 5 
210 C 4.2600000 0.6477654 5 
0 G 5.1800000 0.5112729 5 
15 G 4.8600000 0.3325658 5 
30 G 4.8400000 0.3325658 5 
45 G 4.8800000 0.2853069 5 
60 G 4.9000000 0.3188521 4 
75 G 4.5400000 0.3944617 5 
90 G 4.1000000 0.4582576 5 
105 G 4.3000000 0.3255764 5 
120 G 4.2000000 0.2097618 5 
135 G 3.8400000 0.1469694 5 
150 G 3.6600000 0.1720465 5 
165 G 3.5400000 0.2420744 5 
180 G 3.4200000 0.2745906 5 
195 G 2.9600000 0.2694439 5 











APPENDIX 6 – Blood gas mean and SEM 
 
Time  Treatment Variable Mean Std. Error N 
0 C pH 7.2240000 0.0120830 5 
0 C pCO2 57.2000000 4.1880783 5 
0 C pO2 549.8000000 35.2298169 5 
0 C HCO3 21.6400000 0.9222798 5 
0 C TCO2 25.1800000 1.3305638 5 
0 C BE -3.9600000 1.2675173 5 
0 C O2SAT 99.8800000 0.0200000 5 
120 C pH 7.2160000 0.0401995 5 
120 C pCO2 61.6000000 9.1192105 5 
120 C pO2 536.2000000 44.6345158 5 
120 C HCO3 22.0800000 1.3908271 5 
120 C TCO2 26.2800000 1.9160898 5 
120 C BE -3.1600000 1.8629546 5 
120 C O2SAT 99.8400000 0.0400000 5 
210 C pH 7.1920000 0.0396737 5 
210 C pCO2 63.0000000 11.5628716 5 
210 C pO2 534.0000000 25.1495527 5 
210 C HCO3 21.3800000 1.4722092 5 
210 C TCO2 25.0800000 2.3658825 5 
210 C BE -5.0000000 1.5129441 5 
210 C O2SAT 99.8200000 0.0200000 5 
0 G pH 7.3080000 0.0315278 5 
0 G pCO2 43.0000000 4.5055521 5 
0 G pO2 592.4000000 25.2677660 5 
0 G HCO3 20.8200000 1.1749043 5 
0 G TCO2 22.5800000 1.6044937 5 
0 G BE -3.8400000 1.5131424 5 
0 G O2SAT 99.9000000 0 5 
120 G pH 7.2300000 0.0380789 5 
120 G pCO2 37.4000000 4.9457052 5 
120 G pO2 500.2000000 26.3427409 5 
120 G HCO3 15.8800000 1.1253444 5 
120 G TCO2 16.6000000 1.7401149 5 
120 G BE -10.3600000 1.6271447 5 
120 G O2SAT 99.8200000 0.0200000 5 
210 G pH 7.2920000 0.0220000 5 
210 G pCO2 37.4000000 3.7094474 5 
210 G pO2 543.8000000 39.5011392 5 
210 G HCO3 18.3200000 0.5969925 5 
210 G TCO2 18.9400000 1.2726351 5 
210 G BE -7.3200000 0.9800000 5 
210 G O2SAT 99.8600000 0.0244949 5 
 95 
 96 
0 I pH 7.2640000 0.0265707 5 
0 I pCO2 40.2000000 2.6720778 5 
0 I pO2 471.4000000 4.0570926 5 
0 I HCO3 17.9400000 0.7580237 5 
0 I TCO2 19.6200000 1.0379788 5 
0 I BE -7.1000000 1.1273864 5 
0 I O2SAT 99.8200000 0.0200000 5 
120 I pH 7.1420000 0.0313688 5 
120 I pCO2 48.2000000 2.8178006 5 
120 I pO2 471.4000000 20.5538318 5 
120 I HCO3 15.0200000 1.3165865 5 
120 I TCO2 17.9200000 1.2527570 5 
120 I BE -10.9400000 1.3358892 5 
120 I O2SAT 99.7600000 0.0244949 5 
210 I pH 7.1540000 0.0304302 5 
210 I pCO2 50.0000000 2.5884358 5 
210 I pO2 497.6000000 30.4131550 5 
210 I HCO3 15.9800000 1.1560277 5 
210 I TCO2 19.1000000 0.9813256 5 
210 I BE -9.7800000 1.0758253 5 
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